WO2008038964A1 - Geldanamycin derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and agent for the prevention and treatment of tumor containing the same as an active ingredient - Google Patents

Geldanamycin derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and agent for the prevention and treatment of tumor containing the same as an active ingredient Download PDF

Info

Publication number
WO2008038964A1
WO2008038964A1 PCT/KR2007/004645 KR2007004645W WO2008038964A1 WO 2008038964 A1 WO2008038964 A1 WO 2008038964A1 KR 2007004645 W KR2007004645 W KR 2007004645W WO 2008038964 A1 WO2008038964 A1 WO 2008038964A1
Authority
WO
WIPO (PCT)
Prior art keywords
chemical formula
ester
docosa
trioxo
aza
Prior art date
Application number
PCT/KR2007/004645
Other languages
French (fr)
Inventor
Young-Soo Hong
Kyeong Lee
Jung Joon Lee
Yinlan Jin
Woncheol Kim
Original Assignee
Korea Research Institute Of Bioscience And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute Of Bioscience And Biotechnology filed Critical Korea Research Institute Of Bioscience And Biotechnology
Publication of WO2008038964A1 publication Critical patent/WO2008038964A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings

Definitions

  • the present invention relates to a geldanamycin derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and an agent for the prevention and treatment of cancers, comprising the same as an active ingredient .
  • geldanamycin is a compound with a polyketide backbone, biosynthesized initially from 3-amino-5-hydroxybenzoic acid (AHBA) , and these compounds were found to have antibacterial, antifungal, antiviral and anticancer activity over a period from 1970 to 2000.
  • AHBA 3-amino-5-hydroxybenzoic acid
  • Hsp90 which is a cellular chaperone protein, which led to the finding that the antitumor activity of geldanamycin results from its ability to inhibit the function of Hsp90, which plays an important role in the structural stability of various Hsp90 client proteins including tyrosine kinase, rather than to inhibit the activity of tyrosine kinase, which functions as an oncogenic protein.
  • Hsp90 inhibitors for anticancer therapy have induced the development of chemically synthesized derivatives of geldanamycin, such as 17-allyamino-demethoxygeldanamycin (17-AAG) and 17- (dimethylaminoethylamino) -17-demethoxygeldanamycin (17- DMAG), as Hsp90 inhibitors for anticancer therapy.
  • geldanamycin such as 17-allyamino-demethoxygeldanamycin (17-AAG) and 17- (dimethylaminoethylamino) -17-demethoxygeldanamycin (17- DMAG
  • ⁇ . S. Application No. 10/212,962 discloses benzoquinone ansamycin analogues useful in the treatment of cancers and other diseases caused by undesirable hyperplasia of cells and a preparation method thereof.
  • Korean Patent Application No. 2003-7008551 describes novel geldanamycin derivatives and a preparation method thereof.
  • Korean Patent Application No. 2004-7004202 discloses a method for the chemical synthesis of 17-allyl amino geldanamycin and other ansamycins .
  • geldanamycin derivatives which are chemically modified from the geldanamycin compounds biosynthesized by mutant Streptomyces hygroscopicus subsp. duamyceticus strains, in which genes responsible for the biosynthesis of geldanamycin are mutated, were found to have excellent anticancer activity and to be useful in the treatment of various cancer-related diseases.
  • Disclosure [Technical Problem]
  • the present invention provides 1) geldanamycin derivatives or pharmaceutically acceptable salts thereof, 2) a preparation method thereof, and 3) an agent useful as a preventive and therapeutic for cancerous diseases, an Hsp90 inhibitor, an antibiotic agent, an antifungal agent, an antiviral agent, an immunosuppressor, a therapeutic for degenerative nerve diseases, or an anti-inflammatory agent.
  • a pharmaceutical composition comprising the derivatives according to the present invention as an active ingredient is useful in the prevention and treatment of various cancer diseases.
  • geldanamycin derivatives of the present invention can be used as antibiotics, antifungal agents, antiviral agents, immuno-suppressors, therapeutics for degenerative nerve diseases, anti-inflammatory agents, etc., because they show inhibitory activity against Hsp90, like geldanamycin.
  • FIG. 1 is a schematic view of an Hsp90 alpha gene showing restriction enzyme sites with the distinctive indication of an ATP-binding site and a region used in expression.
  • FIG. 2 is a photograph showing the results of SDS-PAGE performed with the Hsp90 isolated and purified in Experimental Example 1-1.
  • FIG. 3 is a photograph showing the inhibition of Hsp90 activity over time after treatment with 1 ⁇ M of the geldanamycin derivative of Example 2, resulting in the inhibition of ErbB2 activity.
  • the present invention provides a geldanamycin derivative represented by the following Chemical Formula 1: [Chemical Formula l]
  • X is -OR 1 or -NHR 2 wherein Ri is Ci-C 5 alkyl, and R 2 is Ci-C 5 alkyl, Ci-C 5 alkenyl, mono- or di-Ci ⁇ C 5 alkylamino-Ci ⁇ C 5 alkylamino, halogen-substituted Ci-C 5 alkylamino, or 3 ⁇ 7-atom- membered heterocycloalkyl-substituted Ci-C 5 alkylamino, wherein the heterocycloalkyl contains at least one heteroatom;
  • Y and Z are independently hydrogen, -COR 3 or -CONHR 4 wherein R 3 is Ci-C 5 alkyl carbonyl-Ci ⁇ C 5 alkyl and R 4 is hydrogen or Ci-C 5 alkyl; and carbon atoms at positions 4 and 5 may have a single bond or a double bond therebetween.
  • X is -ORi or -NHR 2 wherein Ri is Ci-C 3 alkyl, and R 2 is Ci-C 3 alkyl, Ci-C 3 alkenyl, mono- or di-Ci ⁇ C 3 alkylamino-Ci ⁇ C 3 alkylamino, halogen-substituted Ci-C 3 alkylamino, or 3-5-atom- membered heterocycloalkyl-substituted Ci-C 3 alkylamino, wherein the heterocycloalkyl contains at least one heteroatom;
  • Y and Z are independently hydrogen, -COR 3 or -CONHR 4 wherein R 3 is Ci-C 3 alkyl carbonyl-Ci ⁇ C 3 alkyl and R 4 is hydrogen or Ci-C 3 alkyl; and carbon atoms at positions 4 and 5 may have a single bond or a double bond therebetween.
  • X is methoxy, ethylamino, allylamino, 2-N,N-dimethylamino- ethylamino, 2-N,N-diethylamino-ethylamino, 2-pyrrolidin-l- ylethylamino, 2-morpholin-4-ylethylamino, 3-imidazol-3- ylpropylamino or 2-fluoroethylamino,
  • Y and Z are independently hydrogen, acetylmethylcarbonyl, carbamoyl or methylcarbamoyl; and carbon atoms at positions 4 and 5 may have a single bond or a double bond therebetween.
  • geldanamycin derivatives of Chemical Formula 1 include: 1) carbamic acid 9-carbamoyloxy-8, 14, 19-trimethoxy- 4, 10, 12, 16-tetramethyl-3, 20, 22-trioxo-2-aza- bicyclo[16.3.1]docosa-l (21) , 4, 10, 18-tetraen-13-yl ester;
  • the geldanamycin derivatives of the present invention may be used as free acid or bases or pharmaceutically acceptable salts.
  • the geldanamycin derivatives of the present invention may be used in the form of acid or base addition salts.
  • acid addition salts may be hydrochloride, trifluoroacetic acid, citric acid, lactic acid, maleic acid or fumaric acid
  • base addition salts may be sodium salts, potassium salts, calcium salts or amine-based organic salts.
  • the present invention provides a method for preparing a geldanamycin derivative of Chemical Formula 1 from the starting material 2 of Chemical Formula 2, as illustrated in Reaction Scheme 1.
  • a and B of Chemical Formula 2 are independently hydrogen or a carbamoyl group; carbons between positions 4 and 5 in the starting material 1 and the product 2 are linked via a double bone or a single bond; X, Y and Z of the product 1 are respectively as defined in Chemical Formula 1)
  • the starting material 2 can be represented by the following Chemical Formulas 2a ⁇ 2d.
  • the compound of Chemical Formula 2a may be biologically obtained from a culture of a carbamoyltransferase gene (gel8)- inactivated strain (Streptomyces hygroscopicus ACl) of
  • Streptomyces hygroscopicus subsp. duamyceticus or chemically synthesized through the dicarbamoyl reaction of geldanamycin.
  • the compound of Chemical Formula 2b can be obtained from a culture of Streptomyces hygroscopicus subsp. duamyceticus or from a culture of a microorganism producing geldanamycin as a secondary metabolite.
  • the compound of Chemical Formula 2c which has a single bond between carbons at positions 4 and 5 of geldanamycin, can be obtained form a culture of a mutant of Streptomyces hygroscopicus subsp. duamyceticus in which a reductase of carbons at positions 4 and 5 of geldanamycin, can be obtained form a culture of a mutant of Streptomyces hygroscopicus subsp. duamyceticus in which a reductase of carbons at positions
  • C4 and C5 of geldanamycin is inactivated (gell ⁇ gene-inactivated strain) or as an intermediate for geldanamycin biosynthesis when a strain of Streptomyces hygroscopicus subsp. duamyceticus is cultured under conditions intended to grow the strain slowly.
  • the compound of Chemical Formula 2d can be obtained through a chemical carbamoyl reaction from the starting material geldanamycin of Chemical Formula 2b. [Chemical Formula 2a]
  • Preparation Method 1 The starting material of Chemical Formula 2a is reacted with trichloroacetyl isocyanate in an organic solvent, followed by hydrolysis in the presence of excess Al 2 O 3 to produce the compound of Chemical Formula Ia, as illustrated in Chemical Scheme 2.
  • the solvent is preferably dichloromethane or dichloroethane.
  • the reaction is preferably performed at room temperature after the addition of trichloroacetyl isocyanate to the solvent at a temperature as low as 0 ⁇ 5°C.
  • AI 2 O 3 serves as a catalyst. The reaction is terminated when the compound of Chemical Formula 2a is completely consumed, as monitored with thin layer chromatography.
  • Preparation Method 2 After the completion of Preparation Method 1, Compound Ia is reacted with an amine compound in an organic solvent to produce the compound represented by Chemical Formula Ib, as shown in Reaction Scheme 3, below.
  • the amine compound useful in Preparation Method 2 may be alkyl amine such as ethyl amine; alkenylamine such as allylamine; alkyl-substituted mono- or dialkylaminoalkylamine, such as 2-N,N- dimethylamino-ethylamine and 2-N,N-diethylamino-ethylamine; halogen-substituted haloalkylamine, such as 2-fluoroethylamine; or one or two homo- or heteroatom-containing heterocycloalkyl- substituted alkylamines, such as 1- (2-aminoethyl) pyrrolidine, 4- (2-aminoethyl)morpholine, and 1- (3-aminopropyl) imidazole.
  • alkyl amine such as ethyl amine
  • alkenylamine such as allylamine
  • Useful in Preparation Method 2 is an organic solvent, examples of which include dichloromethane and dichloroethane .
  • the reaction is preferably performed at room temperature.
  • the reaction is terminated when the starting material of Chemical Formula Ia is completely consumed, which can be monitored by thin layer chromatography.
  • Useful in the reaction is an organic solvent, such as tetrahydrofuran (THF) .
  • THF tetrahydrofuran
  • the reaction is preferably performed at room temperature.
  • DMAP serves as a catalyst.
  • the base useful in this method may be Hunig's base (N,N-diisopropylethylamine) or triethylamine.
  • Dichloromethane or dichloroethane may be used as a preferable solvent for this reaction.
  • the reaction solution is preferably stirred for 12 hours or longer prior to the addition of the amine compound and for 1-2 hours after the addition of the amine compound.
  • the amine compound useful in Preparation Method 4 may be alkyl amine such as ethyl amine; alkenylamine such as allylamine; alkyl-substituted mono- or dialkylaminoalkylamine, such as 2-N,N- dimethylamino-ethylamine and 2-N,N-diethylamino-ethylamine; halogen-substituted haloalkylamine, such as 2-fluoroethylamine; or halogen-substituted haloalkylamine, such as 2- fluoroethylamine; or aminoalkyl-substituted heterocycloalkyl containing one or two homo- or heteroatoms, such as l-(2- aminoethyl) pyrrolidine, 4- (2-aminoethyl)morpholine, and l-(3- aminopropyl) imidazole .
  • the reaction is terminated when the starting material of Chemical Formula 2a
  • the organic solvent useful in the reaction is dichloromethane or dichloroethene .
  • the reaction is preferably performed at room temperature after trichloroacetyl isocyanate is added at a temperature of 0 ⁇ 5°C.
  • Al 2 O 3 serves as a catalyst.
  • Preparation Method 6 The product Ie of Preparation Method 6, as illustrated in Reaction Scheme 6, below, is reacted with an amine compound in an organic solvent to produce the compound of Chemical Formula If.
  • the amine compound useful in Preparation Method 6 may be alkyl amine, such as ethyl amine; alkenylamine such as allylamine; alkyl-substituted mono- or dialkylaminoalkylamine, such as 2-N,N-dimethylamino-ethylamine and 2-N,N-diethylamino- ethylamine; halogen-substituted haloalkylamine, such as 2- fluoroethylamine; or aminoalkyl-substituted heterocycloalkyl containing one or two homo- or heteroatoms, such as l-(2- aminoethyl) pyrrolidine, 4- (2-aminoethyl)morpholine, and l-(3- aminopropyl) imidazole.
  • alkyl amine such as ethyl amine
  • alkenylamine such as allylamine
  • the organic solvent useful in the reaction is dichloromethane or dichloroethene.
  • the reaction is preferably performed at room temperature for 24 ⁇ 48 hours.
  • the reaction is terminated when the starting material of Chemical Formula Ie is completely consumed, which can be monitored using thin layer chromatography.
  • the amine compound useful in Preparation Method 6 may be alkyl amine such as ethyl amine; alkenylamine such as allylamine/ alkyl-substituted mono- or dialkylaminoalkylamine, such as 2-N,N- dimethylamino-ethylamine and 2-N,N-diethylamino-ethylamine; halogen-substituted haloalkylamine, such as 2-fluoroethylamine; or aminoalkyl-substituted heterocycloalkyl containing one or two homo- or heteroatoms, such as 1- (2-aminoethyl) pyrrolidine, 4- (2- aminoethyl)morpholine, and 1- (3-aminopropyl) imidazole.
  • alkyl amine such as ethyl amine
  • alkenylamine such as allylamine/ alkyl-substituted mono- or dialkylaminoalkyl
  • Dichloromethane or dichloroethane is preferably used as the organic solvent for this reaction.
  • the reaction is preferably performed at room temperature for 24 ⁇ 48 hours.
  • the geldanamycin derivatives of the present invention increase in affinity for Hsp90 when the ratio of association constant (Ka) to dissociation constant (Kd) increases, and, in order to inhibit the activity of Hsp90, the geldanamycin derivatives, rather than ATP, should preferentially bind to Hsp90, which is possible because the association constant of the geldanamycin derivatives is greater than that of ATP (refer to Experimental Example 2) .
  • the geldanamycin derivatives according to the present invention were found to inhibit the expression only of ErbB2, one of the client proteins of Hsp90, without a change in the expression of Hsp90 in the breast cancer cell SK-Br3 (refer to Experimental Example 3 and Table 3) .
  • the geldanamycin derivatives according to the present invention or pharmaceutically acceptable salts thereof can be used as potent Hsp90 inhibitors.
  • Hsp90 plays an important role in the growth and metastasis of cancer cells
  • the term "the ability of a material to inhibit Hsp90” it is meant that the material may be used to prevent and treat cancers (Whitesell L. et. al. Proc. Natl. Acad. Sci. USA (1994) 91, 8324-8328; Neckers L. et al. (1999) Invest. New Drugs 17, 361-373; Piper P.W. (2001) Curr. Opin. Investing Drugs 2(11) 1606-1610; Whitesell L. & Lindquist S. L. (2005) Nature Reviews 5, 761-772; Workman P. (2004) Trends in Molecular Medicine 10(2) 47-51) .
  • the geldanamycin derivatives of the present invention or the pharmaceutically acceptable salts thereof can be applied to the prevention and treatment of various cancerous diseases.
  • cancerous diseases which can be treated with the geldanamycin derivatives of the present invention include liver cancer, stomach cancer, colon cancer, bone cancer, pancreatic cancer, head and neck cancer, uterine cancer, ovarian cancer, rectal cancer, esophageal cancer, small intestine cancer, periproctic cancer, cancerous Fallopian tube tumor, cancerous endometrioma, cancerous cervical tumors, cancerous vaginal tumors, cancerous vulval tumors, Hodgkin' s disease, prostate cancer, bladder cancer, kidney cancer, ureter cancer, cancerous renal tumors, cancerous tumors of the renal pelvis, tumors of the central nervous system (CNS), and breast cancer.
  • CNS central nervous system
  • the ability of a material to inhibit Hsp90 it is also meant that the material may be used as an antibiotic, an antifungal agent, an antiviral agent, an immunosuppressor, a therapeutic for the treatment of degenerative nerve diseases or an anti-inflammatory agent
  • Antibiotics Takahashi A. et al. (2003) PNAS 100(20) 11777-11782; Agbessi S. et al. (2003) Appl. Microbiol. Biotechnol 62, 233-238
  • Antifungal Agents Cardenas M. E. et al. (1999) Clinical Microbiology Review 12(4) 583-611; Antiviral Agents, Li Y. et al.
  • the geldanamycin derivatives or pharmaceutically acceptable salts thereof can be used as an antibiotic, an antifungal agent, an antiviral agent, an immunosuppressor, a therapeutic for the treatment of degenerative nerve diseases or an anti-inflammatory agent, in accordance with the present invention.
  • a pharmaceutical composition comprising the derivatives of Chemical Formula 1 or pharmaceutically acceptable salts thereof as an active ingredient in accordance with the present invention can be administered either orally or non-orally, and may be provided in general medicine forms .
  • the derivatives according to the present invention can be formulated in combination with a diluent or excipient, such as a filler, a thickening agent, a binder, a wetting agent, a disintegrant, a surfactant, etc.
  • Solid agents intended for oral administration of the compound of the present invention may be in the form of tablets, pills, powders, granules, capsules, and the like. These solid agents are formulated in combination with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, or gelatine. Besides, a lubricant, such as magnesium stearate, talc and the like, may also be added. Liquid agents intended for oral administration include suspensions, internal use solutions, emulsion, syrups, and the like.
  • non-oral dosage forms of the compound of the present invention include sterile injections, suspensions, emulsions, freeze-dried agents, and suppositories.
  • non-aqueous solvents and suspensions made from propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and esters such as ethyl oleate may be used.
  • the specific dosage level of the derivatives according to the present invention for specific patients may be varied depending on patient's body weight, age, sex, health status, diet, time of administration, method of administration, rate of excretion, severity of disease and other conditions.
  • the pharmaceutical composition may be administered in a single dose or in two or three doses per day, each dose ranging from 1 ⁇ 250 mg/kg on the basis of the compound of the present invention. It is obvious to those skilled in the art that the geldanamycin derivatives in accordance with the present invention various have biological activities similar to well-known those of geldanamycin and other biological activities inferable there from, as well as the anti-cancer activity described above.
  • the fractions containing the starting material (2a) were made to pass through a Sephadex LH-20 column and further purified by HPLC [YMC J' sphere ODS-H80, 150 20 mm i.d., methanol-water (0.05% acetic acid) gradient, 10 ml/min] to produce the subject compound as a yellow powder.
  • the fraction was analyzed in comparison with a standard product using HPLC. mp: 80-83 0 C;
  • the fractions containing the starting material (2b) were made to pass through a Sephadex LH-20 column and further purified by HPLC [YMC J' sphere ODS-H80, 150 20 mm i.d., methanol-water (0.05% acetic acid) gradient, 10 ml/min] to produce the subject compound as a yellow powder.
  • the fraction was analyzed in comparison with a standard product using HPLC. mp: 250-254°;
  • a Streptomyces hygroscopicus subsp. duamyceticus strain in which a gene (gel25) sharing high homology with cytochrome 450 is inactivated was cultured at 28°C for 5 days in 3 liters of a yeast extract-malt extract (YEME) medium, which was or was not supplemented with 360 g/1 of sucrose, functioning to retard the growth rate of the strain, so that a product from the strain was accumulated in the medium.
  • the culture was extracted twice with ethylacetate and the extract was filtered to remove insoluble materials therefrom. After the concentration of the filtrate, the concentrate was fractionated into ethylacetate and water.
  • the fractions thus obtained were purified by silical gel chromatography using chloroform-methanol .
  • the fractions containing the starting material (2a) were made to pass through a Sephadex LH-20 column and further purified by HPLC [YMC J' sphere ODS-H80, 150 20 mm i.d., methanol-water (0.05% acetic acid) gradient, 10 ml/min] to produce the subject compound as a yellow powder.
  • HPLC YMC J' sphere ODS-H80, 150 20 mm i.d., methanol-water (0.05% acetic acid) gradient, 10 ml/min
  • EXAMPLE 1 Preparation of Carbamic acid 9-carbamoyloxy-8 , 14 , 19- trimethoxy-4 , 10,12 , 16-tetramethyl-3,20 ,22-trioxo-2-aza- bicyclo [16.3.1]docosa-1 (21) ,4 ,10 ,18-tetraen-13-yl ester (AC23)
  • EXftMPLE 2 Preparation of Carbamic acid 9-carbamoyloxy-19- ethylamino-8 ,14-dimeth ⁇ 3qf-4 , 10 , 12 ,16-tetramethyl-3,20 ,22-trioxo- 2-aza-bicydo [16.3.1]docosa-1 (21) ,4 , 10,18-tetraen-13- ⁇ l ester(AC217)
  • EXAMPLE 3 Preparation of Carbamic acid 19-allylamino-9- carbamoyloxy-8 , 14-dimethoxy-4 , 10,12 , 16-tetratnethyl-3,20,22- trioxo-2-aza-bicydo[16.3.1]docosa-1 (21) ,4 , 10, 18-tetraen-13-yl ester (AC180)
  • EXAMPLE 4 Preparation of Carbamic acid 9-carbamoyloxy-19- (2- dimethyla ⁇ ino-ethylamino) -8 , 14-dimethoxy-4 , 10 , 12 , 16-tetramethyl- 3,20, 22-trioxo-2-aza-bicydo [16.3.1] docosa-1 (21) , 4 , 10 , 18-tetraen- 13-yl ester (AC218)
  • EXAMPLE 6 Preparation of 3-Oxo-butyric acid 8 , 14 , 19-trimethoxy- 4,10 ,12 , 16-tetxamethyl-3,20 ,22-trioxo-13- (3-oxo-butyrylox ⁇ ) -2- aza-bicy ⁇ lo[16.3.1]docosa-1 (21) ,4 , 10 ,18-tetraen-9-yl ester (AC48)
  • Triethylamine (0.0012 ml, 0.0087 mmol) was slowly added at room temperature to a mixture comprising a catalytically effective amount of 4-dimethylamino-pyridine in tetrahydrofuran (1 ml), the compound of Preparation Example 1 (41.2 mg, 0.079 mmol), and diketene (0.0067 ml, 0.087 mmol).
  • the reaction mixture was stirred overnight and concentrated.
  • EXAMPLE 8 Preparation of Carbamic acid 19-allylatnino-9- carbamoyloxy-8 , 14-dimethoxy-4, 10 ,12 , 16-tetramethyl-3,20 ,22- trioxo-2-aza-bicyclo [16.3.1]docosa-1 (21) ,4 , 6,10 , 18-pentaen-13-yl ester (ACC199)
  • EXAMPLE 10 Preparation of Carbamic acid 9-carbamoyloxy-19- (2- di ⁇ thylamino-ethylamino) -8 , 14-dimethoxy-4 ,10 , 12 , 16-tetramethyl- 3,20 ,22-trioxo-2-aza-bicydo [16.3.1]docosa-1 (21) ,4 , 6, 10 , 18- pentaen-13-yl ester (AC221)
  • EXMAPLE 11 Preparation of Carbamic acid 9-carbamoyloxy-8,14- dimethoxy-4 , 10 , 12 , 16-tetramethyl-3,20 ,22-trioxo-19- (2-p ⁇ rrolidin- 1-yl-ethylamino) -2-aza-bicydo [16.3.1]docosa-1 (21) ,4 , 6,10, 18- pentaen-13-yl ester (AC225)
  • EXAMPLE 12 Preparation of Carbamic acid 19-ethylamino-13- hydroxy-8 , 14-dimethox ⁇ -4 , 10 , 12 , 16-tetrameth ⁇ l-3 , 20 , 22-trioxo-2- aza-bicydo [16.3.1] docosa-1 (21) , 4 , 10 , 18-tetraen-9-yl ester
  • EXAMPLE 13 Preparation of Carbamic acid 19-allyla ⁇ nino-13- hydroxy-8 ,14-dimethoxy-4 , 10 , 12 , 16-tetramethyl-3,20 ,22-trioxo-2- aza-bicydo[16.3.1]docosa-1 (21) ,4, 10 , 18—tetraen-9-yl ester (AC220)
  • EXAMPLE 14 Preparation of Carbamic acid 19- (2-dimethylamino- ethylamino) -13-hydroxy-8,14-dimethoxy-4,10,12 ,16-tetramethyl- 3,20,22-trioxo-2-aza-bicyclo[16.3.1]docosa-1 (21) ,4 ,10 , 18-tetraen- 9-yl ester (AC196)
  • EXAMPLE 16 Preparation of Carbamic acid 13-hydroxy-8,14- dimethoxy-4 , 10 , 12 , 16-tetramethyl-3,20 ,22-trioxo-19- (2-pyrrolidin- 1-yl-ethylamino) -2-aza-bicydo [16.3.1]docosa-1 (21) ,4 ,10 , 18- tetraen-9-yl ester
  • EXAMPLE 17 Preparation of Carbamic acid 13-hydroxy-8,14- dimethoxy-4,10,12 ,16-tetramethyl-19- (2-morpholin-4-yl- ⁇ thylamino) -3,20,22-trioxo-2-aza-bicydo [16.3.1]docosa- 1 (21) ,4 ,10,18-tetraen-9-yl ester
  • EXAMPLE 18 Preparation of Carbamic acid 13-hydroxy-19- (3- imidazol-1-yl-propylamino) -8 , 14-dimethoxy-4 , 10 , 12 , 16-tetramethyl- 3,20,22-trioxo-2-aza-bicydo [16.3.1] docosa-1 (21) , 4 , 10 , 18-tetraen- 9-yl ester
  • the ATP-binding site domain of Hsp90 was isolated and purified as follows.
  • PCR was performed with a set of primers (forward primer with an Ndel site: 5'-CCA TAT GCC TGA GGA AAC CCA GAC CC-3' and backward primer with an Sail site: 5'-GTC GAC CTT TTC TTC AGC CTC ATC ATC GC-3' ) to amplify an N-terminal region comprising the ATP-binding site domain of Hsp90, and the PCR product was cloned into a pET-22b(+) vector (FIG. 1) which was then transformed into E. coli BL21(DE3).
  • the protein of interest was produced through the overexpression of the gene.
  • coli carrying the plasmid was cultured for about 16 hours in 5 ml of an LB (Luria-Bertani) broth containing ampicillin in an amount of 50 ⁇ g/ml. After 50-fold dilution with 200 ml of a fresh LB broth, the culture was incubated for an additional 2 ⁇ 3 hours . When the OD (optical density) of the culture reached about 0.4 ⁇ 0.8, as measured at 600 nm using a UV spectrophotometer, isopropyl ⁇ -D-thioglucopyranoside (IPTG) was added at a final concentration of 1 mM to induce overexpression, followed by incubation at 37 0 C for an additional 4 hours.
  • IPTG isopropyl ⁇ -D-thioglucopyranoside
  • the cells After being collected by centrifugation (6000 rpm, 10 min) , the cells were suspended in 10 ml of a 100 mM lysis buffer (100 mM NaH 2 PO 4 pH 7.8, 10 mM Tris-HCl, 0.2 mM PMSF, 0.2 mM ⁇ -mercaptoethanol) and lyzed through sonication. After the removal of cell debris by centrifugation, the expression of the protein of interest was identified using SDS-PAGE.
  • a 100 mM lysis buffer 100 mM NaH 2 PO 4 pH 7.8, 10 mM Tris-HCl, 0.2 mM PMSF, 0.2 mM ⁇ -mercaptoethanol
  • the lysate supernatant was mixed at room temperature for 15 ⁇ 60 min with 1 ml of Ni-NTA resins and gently shaken.
  • the lysate-resin was carefully loaded onto a column which was then treated twice with 4 ml of a wash buffer (100 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, pH 8.0) and finally four times with 0.5 ml of an elution buffer (100 mM NaH 2 PO 4 , 300 itiM NaCl, 200 iriM imidazole, pH 8.0).
  • the fractions thus eluted were subjected to SDS-PAGE, and the results are shown in FIG. 2.
  • a neat protein band was detected at 28 kDa, which corresponds to the molecular weight of the ATP-binding site domain of Hsp90.
  • BIACORE ® is an instrument adapted for measuring protein- protein interaction and binding affinity on a sensor chip, based on Surface Plasmon Resonance (SPR) , an optical phenomenon that enables detection of unlabeled interactants in real time.
  • SPR Surface Plasmon Resonance
  • a CM5 chip one of the most widely used biosensor chips, is coated with dextran with negative charges on the carboxyl groups thereof.
  • Dextran is a straight chain consisting of glucose units and shows almost no nonspecific binding to biomaterials .
  • the N-hydroxysuccinimide-ester can form bonds with primary amino groups of proteins or other biomaterials .
  • a buffer having a low pH because it allows samples to readily reach the surface of the sensor chip.
  • HBS-P buffer for use in immobilizing the N-terminal Hsp90 protein purified in Experimental Example 1-1 on a CM5 chip, HBS-P buffer, commercially available from BIACORE, was identified to provide optimal conditions at pH 4.5, as measured by a preconcentration test. Samples were immobilized to a No. 4 flow cell on the CM5 biosensor chip using standard amine coupling chemistry with a flow rate of 5 ⁇ l/min in HBS-P running buffer.
  • the chip surface was activated with an injection of 50 ⁇ l of N-ethyl- N' - (dimethylaminopropyl) carbodiimide) /N-hydroxysuccinimide into the flow cell, followed by injecting 100 ⁇ l of a dilution of 60 ⁇ l of 1 mg/ml N-terminal Hsp90 protein in 80 ⁇ l of 10 mM sodium acetate buffer (pH 4.5) to immobilize the protein. Excess protein was removed with an injection of 5 ⁇ l of 50 mM sodium hydroxide before the injection of 50 ⁇ l of IM ethanolamine to block the remaining active NHS-ester. Therefore, the immobilization of the N-terminal Hsp90 protein of 4230 RU was achieved. As a control, BSA was immobilized to a No. 3 flow cell in the same manner as described above.
  • geldanaitiycin (Preparation Example 2) and the compounds of Chemical Formula 1 were dissolved in ethanol to give a 10 mM solution which was then diluted with 2% ethanol- supplemented HBS-P buffer to a series of concentrations of 5,000, 2,500, 1,250, 625, 312 and 156 nM before injection.
  • Kinetic studies were performed on triplicate injection of 30 ⁇ l of each sample with a flow rate of 30 ⁇ l/rain in buffer with 1 min and 2 min set for association time and dissociation time, respectively.
  • a sensorgram was given as a mean value set by subtracting the value of the No.
  • the sensorgrams were corrected by subtracting the control sensorgram, the mean obtained with the running buffer in the same manner, from the mean sensorgram of each sample.
  • the corrected sensorgrams were used to give association constants for samples (Ka (1/ms) means numbers of the association of 1 molar compound with Hsp90 per sec) , dissociation constants for samples (Kd (1/s) means numbers of the dissociation of the complex into individuals per sec) , equilibrium dissociation constants (KD (Kd/ka) refers to dissociation tendency, with higher values corresponding to low affinity) , and the chi-square values (Chi 2 ; a standard statistical measure of closeness of fit; values below 10 are acceptable) , and the results are summarized in Table 2, below.
  • ErbB2 expression levels were monitored over time.
  • SK-Br3 a human breast cancer strain, was cultured at 37 0 C for 24 hours in a 5% CO 2 atmosphere and than treated with a 1 ⁇ M 17-allyl amino geldanamycin solution in DMSO, followed by incubation for the same time period.
  • the cell pellet was homogenized in a lysis buffer (50 mM Tris buffer pH 7.6, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, l%(v/v) protease inhibitor mixture (Sigma #P8340) ) and lyzed by sonication.
  • the lysate was subjected to protein analysis using a BCA method. 50 ⁇ g of each of the protein samples thus obtained was loaded on SDS-PAGE, followed by immunoblotting against ErbB2 and Hsp90. The results are shown in FIG. 3.
  • Hsp90 was observed to experience no change for 8 hours after the treatment with 17-allyl amino geldanamycin. From these observations, it is speculated that the geldanamycin derivatives according to the present invention directly inhibit the activity of Hsp90 by binding to Hsp90, which results in a decrease in the expression of ErbB2, a client protein of Hsp90.
  • the compounds represented by Chemical Formula 1 in accordance with the present invention were assayed for cytotoxicity against cancer cells as follows.
  • SK-Br3 a human breast cancer cell line in which the Hsp90 client protein ErbB2 (kinase, involved in cancer development) is overexpressed, is widely used for the assay of conventional geldanamycin derivatives for anticancer activity.
  • SK-Br3 cells were plated at a density of IxIO 4 cells per well into 96-well plates, incubated at 37 0 C for 24 hours in a 5% CO 2 atmosphere, and treated with 100, 10, 1, 0.1, 0.01, 0.001, 0.0001, 0.00001, and 0 ⁇ M of each sample in DMSO, followed by incubation for 72 hours under the same conditions . Incubation with MTT reagent at 37°C for 4 hours formed formazan within cells. Then, the cells were incubated overnight with a lysis buffer at 37 0 C, followed by measuring absorbance at 570 nm/650 nm using a UV spectrophotometer to calculate IC 50 , and the results are given in Table 3, below.
  • the compounds of Chemical Formula 1 have IC 50 values less than 50 nM for the breast cancer cell line SK-Br3. Particularly, the compounds of Examples 5, 11 and 15 are lower in IC 50 value than the conventional geldanamycin derivative 17-DMAG. From these data, it is understood that the geldanamycin derivatives of Chemical Formula 1 in accordance with the present invention bind to the ATP-binding site of Hsp90 to inhibit the expression and stability of the client proteins thereof, involved in cancer development, such as ErbB2, thus exerting cytotoxicity on cancer cells.
  • the compounds of the present invention are formulated as follows .
  • Lactose Ig The above ingredients were mixed and loaded into an airtight sac to produce powder.
  • the geldanamycin derivatives of Chemical Formula 1 in accordance with the present invention can be applied to anticancer activity.
  • a pharmaceutical composition comprising the derivatives according to the present invention as an active ingredient is useful in the prevention and treatment of various cancer diseases.
  • geldanamycin derivatives of the present invention can be used as antibiotics, antifungal agents, anti- viral agents, immuno-suppressors, therapeutics for degenerative nerve diseases, anti-inflammatory agents, etc., because they show inhibitory activity against Hsp90, like geldanamycin.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are geldanamycin derivatives of Chemical Formula 1, pharmaceutically acceptable salts thereof, a preparation method thereof, and agents for the preparation and treatment of cancerous diseases, comprising the same as an active ingredient. Having inhibitory activity against the chaperone protein Hsp90, which plays an important role in the growth and metastasis of cancer cells, the geldanamycin derivatives can be used as antibiotics, antifungal agents, anti-viral agents, immuno- suppressors, therapeutics for degenerative nerve diseases, or anti-inflammatory agents, in addition to being applied to the treatment of cancerous diseases. (Chemical Formula 1) (wherein, X, Y, and Z are as defined in the specification)

Description

[DESCRIPTION]
[invention Title]
GELDANAMYCIN DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND AGENT FOR THE PREVENTION AND TREATMENT OF TUMOR CONTAINING THE SAME AS AN ACTIVEINGREDIENT
[Technical Field]
The present invention relates to a geldanamycin derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and an agent for the prevention and treatment of cancers, comprising the same as an active ingredient .
[Background Art]
Like herbimycin, macbecin and reblastatin, geldanamycin is a compound with a polyketide backbone, biosynthesized initially from 3-amino-5-hydroxybenzoic acid (AHBA) , and these compounds were found to have antibacterial, antifungal, antiviral and anticancer activity over a period from 1970 to 2000.
It was discovered by Neckers et al. in 1994 that geldanamycin occupies the ATP-binding site on heat shock protein
90 (hereinafter referred to as "Hsp90") , which is a cellular chaperone protein, which led to the finding that the antitumor activity of geldanamycin results from its ability to inhibit the function of Hsp90, which plays an important role in the structural stability of various Hsp90 client proteins including tyrosine kinase, rather than to inhibit the activity of tyrosine kinase, which functions as an oncogenic protein. Physiologically important roles of Hsp90 have induced the development of chemically synthesized derivatives of geldanamycin, such as 17-allyamino-demethoxygeldanamycin (17-AAG) and 17- (dimethylaminoethylamino) -17-demethoxygeldanamycin (17- DMAG), as Hsp90 inhibitors for anticancer therapy. ϋ. S. Application No. 10/212,962 discloses benzoquinone ansamycin analogues useful in the treatment of cancers and other diseases caused by undesirable hyperplasia of cells and a preparation method thereof.
Korean Patent Application No. 2003-7008551 describes novel geldanamycin derivatives and a preparation method thereof. Korean Patent Application No. 2004-7004202 discloses a method for the chemical synthesis of 17-allyl amino geldanamycin and other ansamycins .
Leading to the present invention, geldanamycin derivatives, which are chemically modified from the geldanamycin compounds biosynthesized by mutant Streptomyces hygroscopicus subsp. duamyceticus strains, in which genes responsible for the biosynthesis of geldanamycin are mutated, were found to have excellent anticancer activity and to be useful in the treatment of various cancer-related diseases. [Disclosure] [Technical Problem]
It is an object of the present invention to provide a geldanamycin derivative . It is another object of the present invention to provide a method for preparing the geldanamycin derivative .
It is a further object of the present invention to provide an agent for the prevention and treatment of cancerous diseases, comprising the geldanamycin derivative as an active ingredient. It is still a further object of the present invention to provide an Hsp90 inhibitor, comprising the geldanamycin derivative as an active ingredient.
It is still another object of the present invention to provide an agent useful as an antibiotic, an antifungal agent, an antiviral agent, an immunosuppressor, a therapeutic for degenerative nerve diseases, and an anti-inflammatory agent, comprising the geldanamycin derivative as an active ingredient.
[Technical Solution]
In accordance with an aspect thereof, the present invention provides 1) geldanamycin derivatives or pharmaceutically acceptable salts thereof, 2) a preparation method thereof, and 3) an agent useful as a preventive and therapeutic for cancerous diseases, an Hsp90 inhibitor, an antibiotic agent, an antifungal agent, an antiviral agent, an immunosuppressor, a therapeutic for degenerative nerve diseases, or an anti-inflammatory agent.
[Advantageous Effects]
With inhibitory activity against the chaperone protein
Hsp90, which plays an important role in the growth and metastasis of cancer cells, the geldanamycin derivatives of Chemical Formula
1 in accordance with the present invention can be applied to anticancer activity. Thus, a pharmaceutical composition comprising the derivatives according to the present invention as an active ingredient is useful in the prevention and treatment of various cancer diseases.
In addition, the geldanamycin derivatives of the present invention can be used as antibiotics, antifungal agents, antiviral agents, immuno-suppressors, therapeutics for degenerative nerve diseases, anti-inflammatory agents, etc., because they show inhibitory activity against Hsp90, like geldanamycin.
[Description of Drawings]
FIG. 1 is a schematic view of an Hsp90 alpha gene showing restriction enzyme sites with the distinctive indication of an ATP-binding site and a region used in expression. FIG. 2 is a photograph showing the results of SDS-PAGE performed with the Hsp90 isolated and purified in Experimental Example 1-1.
FIG. 3 is a photograph showing the inhibition of Hsp90 activity over time after treatment with 1 μM of the geldanamycin derivative of Example 2, resulting in the inhibition of ErbB2 activity.
[Best Mode]
Below, a detailed description will be given of the present invention.
In accordance with an aspect thereof, the present invention provides a geldanamycin derivative represented by the following Chemical Formula 1: [Chemical Formula l]
Figure imgf000006_0001
wherein,
X is -OR1 or -NHR2 wherein Ri is Ci-C5 alkyl, and R2 is Ci-C5 alkyl, Ci-C5 alkenyl, mono- or di-Ci~C5 alkylamino-Ci~C5 alkylamino, halogen-substituted Ci-C5 alkylamino, or 3~7-atom- membered heterocycloalkyl-substituted Ci-C5 alkylamino, wherein the heterocycloalkyl contains at least one heteroatom;
Y and Z are independently hydrogen, -COR3 or -CONHR4 wherein R3 is Ci-C5 alkyl carbonyl-Ci~C5 alkyl and R4 is hydrogen or Ci-C5 alkyl; and carbon atoms at positions 4 and 5 may have a single bond or a double bond therebetween.
In a preferable embodiment,
X is -ORi or -NHR2 wherein Ri is Ci-C3 alkyl, and R2 is Ci-C3 alkyl, Ci-C3 alkenyl, mono- or di-Ci~C3 alkylamino-Ci~C3 alkylamino, halogen-substituted Ci-C3 alkylamino, or 3-5-atom- membered heterocycloalkyl-substituted Ci-C3 alkylamino, wherein the heterocycloalkyl contains at least one heteroatom;
Y and Z are independently hydrogen, -COR3 or -CONHR4 wherein R3 is Ci-C3 alkyl carbonyl-Ci~C3 alkyl and R4 is hydrogen or Ci-C3 alkyl; and carbon atoms at positions 4 and 5 may have a single bond or a double bond therebetween.
In a more preferable embodiment,
X is methoxy, ethylamino, allylamino, 2-N,N-dimethylamino- ethylamino, 2-N,N-diethylamino-ethylamino, 2-pyrrolidin-l- ylethylamino, 2-morpholin-4-ylethylamino, 3-imidazol-3- ylpropylamino or 2-fluoroethylamino,
Y and Z are independently hydrogen, acetylmethylcarbonyl, carbamoyl or methylcarbamoyl; and carbon atoms at positions 4 and 5 may have a single bond or a double bond therebetween.
Concrete examples of the geldanamycin derivatives of Chemical Formula 1 according to the present invention include: 1) carbamic acid 9-carbamoyloxy-8, 14, 19-trimethoxy- 4, 10, 12, 16-tetramethyl-3, 20, 22-trioxo-2-aza- bicyclo[16.3.1]docosa-l (21) , 4, 10, 18-tetraen-13-yl ester;
2) carbamic acid 9-carbamoyloxy-19-ethylamino-8, 14- dimethoxy-4, 10, 12, 16-tetramethyl-3, 20, 22-trioxo-2-aza- bicyclo [16.3.1] docosa-1 (21) , 4, 10, 18-tetraen-13-yl ester; 3) carbamic acid 19-allylamino-9-carbamoyloxy-8, 14- dimethoxy-4, 10, 12, lβ-tetramethyl-3,20,22-trioxo-2-aza- bicyclo[16.3.1] docosa-1 (21) , 4, 10, 18-tetraen-13-yl ester;
4) carbamic acid 9-carbamoyloxy-19- (2-dimethylamino- ethylamino) -8, 14-dimethoxy-4, 10, 12, 16-tetramethyl-3,20,22-trioxo- 2-aza-bicyclo[16.3.1]docosa-l(21) , 4, 10, 18-tetraen-13-yl ester;
5) carbamic acid 9-carbamoyloxy-19- (2-diethylamino- ethylamino) -8, 14-dimethoxy-4, 10, 12, 16-tetramethyl-3,20,22-trioxo- 2-aza-bicyclo[16.3.1]docosa-l(21),4,10,18-tetraen-13-yl ester; β) 3-oxo-butyric acid 8, 14, 19-trimethoxy-4, 10, 12, 16- tetramethyl-3, 20, 22-trioxo-13- (3-oxo-butyryloxy) -2-aza- bicyclo[16.3.1] docosa-1 (21) , 4, 10, 18-tetraen-9-yl ester;
7) methyl-carbamic acid 8, 14-dimethoxy-4, 10, 12, 16- tetramethyl-19-methylamino-13-methylcarbamoyloxy-3,20,22-trioxo- 2-aza-bicyclo[16.3.1] docosa-1 (21) , 4, 10, 18-tetraen-9-yl ester; 8) carbamic acid 19-allylamino-9-carbamoyloxy-8, 14- dimethoxy-4, 10,12, 16-tetramethyl-3, 20, 22-trioxo-2-aza- bicyclo[16.3.1] docosa-1 (21), 4, 6, 10, 18-pentaen-13-yl ester;
9) carbamic acid 9-carbamoyloxy-19- (2-dimethylamino- ethylamino) -8, 14-dimethoxy-4, 10, 12, 16-tetramethyl-3, 20, 22-trioxo- 2-aza-bicyclo[16.3.1] docosa-1 (21) ,4, 6, 10, 18-pentaen-13-yl ester;
10) carbamic acid 9-carbamoyloxy-19- (2-diethylamino- ethylamino) -8, 14-dimethoxy-4, 10, 12, 16-tetramethyl-3, 20, 22-trioxo- 2-aza-bicyclo[lβ.3.1]docosa-l(21) , 4, 6, 10, 18-pentaen-13-yl ester;
11) carbamic acid 9-carbamoyloxy-8, 14-dimethoxy- 4, 10, 12, 16-tetramethyl-3, 20, 22-trioxo-19- (2-pyrrolidin-l-yl- ethylamino) -2-aza-bicyclo [16.3. l]docosa-l (21), 4,6, 10, 18-pentaen- 13-yl ester;
12) carbamic acid 19-ethylamino-13-hydroxy-8, 14-dimethoxy- 4,10, 12, 16-tetramethyl-3, 20, 22-trioxo-2-aza- bicyclo[16.3.1]docosa-l (21) , 4, 10, 18-tetraen-9-yl ester; 13) carbamic acid 19-allylamino-13-hydroxy-8, 14-dimethoxy- 4, 10, 12, 16-tetramethyl-3, 20,22-trioxo-2-aza- bicyclo[16.3.1]docosa-l(21) , 4, 10, 18-tetraen-9-yl ester;
14) carbamic acid 19- (2-dimethylaminc—ethylamino) -13- hydroxy-8, 14-dimethoxy-4, 10, 12, 16-tetramethyl-3, 20, 22-trioxo-2- aza-bicyclo[16.3.1]docosa-l (21) ,4, 10, 18-tetraen-9-yl ester;
15) carbamic acid 19- (2-diethylamino-ethylamino) -13- hydroxy-8, 14-dimethoxy-4, 10, 12, 16-tetramethyl-3, 20, 22-trioxo-2- aza-bicyclo[16.3.1]docosa-l (21) , 4, 10, 18-tetraen-9-yl ester;
16) carbamic acid 13-hydroxy-8, 14-dimethoxy-4, 10, 12, 16- tetramethyl-3, 20, 22-trioxo-19- (2-pyrrolidin-l-yl-ethylamino) -2- aza-bicyclo[16.3.1]docosa-l (21) ,4, 10, 18-tetraen-9-yl ester;
17) carbamic acid 13-hydroxy-8, 14-dimethoxy-4, 10, 12, 16- tetramethyl-19- (2-morpholin-4-yl-ethylamino) -3,20, 22-trioxo-2- aza-bicyclo[16.3.1]docosa-l (21) , 4, 10, 18-tetraen-9-yl ester; and 18) carbamic acid 13-hydroxy-19- (3-imidazol-l-yl- propylamino) -8, 14-dimethoxy-4, 10, 12, 16-tetramethyl-3, 20, 22- trioxo-2-aza-bicyclo [16.3.1] docosa-1 (21) , 4, 10, 18-tetraen-9-yl ester.
The geldanamycin derivatives of the present invention, represented by Chemical Formula 1, may be used as free acid or bases or pharmaceutically acceptable salts. For example, the geldanamycin derivatives of the present invention may be used in the form of acid or base addition salts. Preferably, acid addition salts may be hydrochloride, trifluoroacetic acid, citric acid, lactic acid, maleic acid or fumaric acid, while base addition salts may be sodium salts, potassium salts, calcium salts or amine-based organic salts.
In addition, it should be noted that solvates and hydrates of the geldanamycin derivatives of Chemical Formula 1 fall within the scope of the present invention.
In accordance with another aspect thereof, the present invention provides a method for preparing a geldanamycin derivative of Chemical Formula 1 from the starting material 2 of Chemical Formula 2, as illustrated in Reaction Scheme 1.
[Reaction Scheme l]
Figure imgf000010_0001
(wherein, A and B of Chemical Formula 2 are independently hydrogen or a carbamoyl group; carbons between positions 4 and 5 in the starting material 1 and the product 2 are linked via a double bone or a single bond; X, Y and Z of the product 1 are respectively as defined in Chemical Formula 1)
In greater detail, the starting material 2 can be represented by the following Chemical Formulas 2a~2d.
The compound of Chemical Formula 2a may be biologically obtained from a culture of a carbamoyltransferase gene (gel8)- inactivated strain (Streptomyces hygroscopicus ACl) of
Streptomyces hygroscopicus subsp. duamyceticus, or chemically synthesized through the dicarbamoyl reaction of geldanamycin.
The compound of Chemical Formula 2b can be obtained from a culture of Streptomyces hygroscopicus subsp. duamyceticus or from a culture of a microorganism producing geldanamycin as a secondary metabolite.
The compound of Chemical Formula 2c, which has a single bond between carbons at positions 4 and 5 of geldanamycin, can be obtained form a culture of a mutant of Streptomyces hygroscopicus subsp. duamyceticus in which a reductase of carbons at positions
C4 and C5 of geldanamycin is inactivated (gellβ gene-inactivated strain) or as an intermediate for geldanamycin biosynthesis when a strain of Streptomyces hygroscopicus subsp. duamyceticus is cultured under conditions intended to grow the strain slowly.
The compound of Chemical Formula 2d can be obtained through a chemical carbamoyl reaction from the starting material geldanamycin of Chemical Formula 2b. [Chemical Formula 2a]
Figure imgf000012_0001
[Chemical Formula 2c]
Figure imgf000012_0002
The preparation method according to the present invention is explained in greater detail as follows.
Preparation Method 1 The starting material of Chemical Formula 2a is reacted with trichloroacetyl isocyanate in an organic solvent, followed by hydrolysis in the presence of excess Al2O3 to produce the compound of Chemical Formula Ia, as illustrated in Chemical Scheme 2. In Preparation Method 1, the solvent is preferably dichloromethane or dichloroethane. The reaction is preferably performed at room temperature after the addition of trichloroacetyl isocyanate to the solvent at a temperature as low as 0~5°C. AI2O3 serves as a catalyst. The reaction is terminated when the compound of Chemical Formula 2a is completely consumed, as monitored with thin layer chromatography.
[Reaction Scheme 2]
Figure imgf000013_0001
21 1a
Preparation Method 2 After the completion of Preparation Method 1, Compound Ia is reacted with an amine compound in an organic solvent to produce the compound represented by Chemical Formula Ib, as shown in Reaction Scheme 3, below.
The amine compound useful in Preparation Method 2 may be alkyl amine such as ethyl amine; alkenylamine such as allylamine; alkyl-substituted mono- or dialkylaminoalkylamine, such as 2-N,N- dimethylamino-ethylamine and 2-N,N-diethylamino-ethylamine; halogen-substituted haloalkylamine, such as 2-fluoroethylamine; or one or two homo- or heteroatom-containing heterocycloalkyl- substituted alkylamines, such as 1- (2-aminoethyl) pyrrolidine, 4- (2-aminoethyl)morpholine, and 1- (3-aminopropyl) imidazole.
Useful in Preparation Method 2 is an organic solvent, examples of which include dichloromethane and dichloroethane . The reaction is preferably performed at room temperature.
The reaction is terminated when the starting material of Chemical Formula Ia is completely consumed, which can be monitored by thin layer chromatography.
[Reaction Scheme 3]
Figure imgf000014_0001
2a ia ih
(wherein, X is as defined in Chemical Formula 1) Preparation Method 3
As illustrated in Route 1 of Reaction Scheme 4, below, the starting material represented by Chemical Formula 2a is reacted with diketene in the presence of 4-dimethylamino pyridine (DMAP) and a base in an organic solvent to produce the compound of
Chemical Formula Ic.
Useful in the reaction is an organic solvent, such as tetrahydrofuran (THF) . The reaction is preferably performed at room temperature. DMAP serves as a catalyst. The base useful in this method may be Hunig's base (N,N-diisopropylethylamine) or triethylamine.
The reaction is terminated upon the complete consumption of the starting material of Chemical Formula 2a, which can be monitored using thin layer chromatography. [Reaction Scheme 4]
Figure imgf000016_0001
id
(wherein, X is as defined in Chemical Formula 1)
Preparation Method 4
As illustrated in Route 2 of Reaction Scheme 4, the starting material of Chemical Formula 2a is reacted with 1,1'- carbonyldimidazole in an organic solvent, followed by the addition of an amine compound to the reaction to produce the compound of Chemical Formula Id.
Dichloromethane or dichloroethane may be used as a preferable solvent for this reaction. The reaction solution is preferably stirred for 12 hours or longer prior to the addition of the amine compound and for 1-2 hours after the addition of the amine compound.
The amine compound useful in Preparation Method 4 may be alkyl amine such as ethyl amine; alkenylamine such as allylamine; alkyl-substituted mono- or dialkylaminoalkylamine, such as 2-N,N- dimethylamino-ethylamine and 2-N,N-diethylamino-ethylamine; halogen-substituted haloalkylamine, such as 2-fluoroethylamine; or halogen-substituted haloalkylamine, such as 2- fluoroethylamine; or aminoalkyl-substituted heterocycloalkyl containing one or two homo- or heteroatoms, such as l-(2- aminoethyl) pyrrolidine, 4- (2-aminoethyl)morpholine, and l-(3- aminopropyl) imidazole . The reaction is terminated when the starting material of Chemical Formula 2a is completely consumed, which can be monitored using thin layer chromatography.
Preparation Method 5 As illustrated in Reaction Scheme 5, below, the starting material of Chemical Formula 2b is reacted with trichloroacetyl isocyanate in an organic solvent, followed by hydrolysis in the presence of AI2O3 to produce the compound of Chemical Formula Ie.
The organic solvent useful in the reaction is dichloromethane or dichloroethene . The reaction is preferably performed at room temperature after trichloroacetyl isocyanate is added at a temperature of 0~5°C. Al2O3 serves as a catalyst.
The reaction is terminated upon the complete consumption of the starting material of Chemical Formula 2b, which can be monitored using thin layer chromatography. [Reaction Scheme 5]
Figure imgf000018_0001
20 1*
Preparation Method 6 The product Ie of Preparation Method 6, as illustrated in Reaction Scheme 6, below, is reacted with an amine compound in an organic solvent to produce the compound of Chemical Formula If.
The amine compound useful in Preparation Method 6 may be alkyl amine, such as ethyl amine; alkenylamine such as allylamine; alkyl-substituted mono- or dialkylaminoalkylamine, such as 2-N,N-dimethylamino-ethylamine and 2-N,N-diethylamino- ethylamine; halogen-substituted haloalkylamine, such as 2- fluoroethylamine; or aminoalkyl-substituted heterocycloalkyl containing one or two homo- or heteroatoms, such as l-(2- aminoethyl) pyrrolidine, 4- (2-aminoethyl)morpholine, and l-(3- aminopropyl) imidazole.
The organic solvent useful in the reaction is dichloromethane or dichloroethene. The reaction is preferably performed at room temperature for 24~48 hours. The reaction is terminated when the starting material of Chemical Formula Ie is completely consumed, which can be monitored using thin layer chromatography. [Reaction Scheme 6]
Figure imgf000019_0001
(wherein, X is as defined in Chemical Formula 1]
Preparation Method 7
As illustrated in Reaction Scheme 7, the starting compound of Chemical Formula 2c is reacted with an amine compound in an organic solvent to provide the compound of Chemical Formula Ig. The amine compound useful in Preparation Method 6 may be alkyl amine such as ethyl amine; alkenylamine such as allylamine/ alkyl-substituted mono- or dialkylaminoalkylamine, such as 2-N,N- dimethylamino-ethylamine and 2-N,N-diethylamino-ethylamine; halogen-substituted haloalkylamine, such as 2-fluoroethylamine; or aminoalkyl-substituted heterocycloalkyl containing one or two homo- or heteroatoms, such as 1- (2-aminoethyl) pyrrolidine, 4- (2- aminoethyl)morpholine, and 1- (3-aminopropyl) imidazole.
Dichloromethane or dichloroethane is preferably used as the organic solvent for this reaction. The reaction is preferably performed at room temperature for 24~48 hours.
The reaction is terminated when the starting material of Chemical Formula 2c is completely consumed, which can be monitored via thin layer chromatography. [Reaction Scheme 7]
Figure imgf000020_0001
(wherein, X is as defined in Chemical Formula 1)
The derivatives of Chemical Formula 1 or pharmaceutically acceptable salts thereof will be explained in greater detail below.
Geldanamycin was tested for binding kinetics with the N- terminal ATP-binding site of Hsp90 on the basis of the fact that when geldanamycin, competing with ATP, occupies the ATP-binding site on Hsp90, it inhibits the chaperone activity of Hsp90 to interfere with the activation and stabilization of client proteins (Prodromous C. et al. (1997) Cell 90, 65- 75) . Accordingly, the geldanamycin derivatives of the present invention increase in affinity for Hsp90 when the ratio of association constant (Ka) to dissociation constant (Kd) increases, and, in order to inhibit the activity of Hsp90, the geldanamycin derivatives, rather than ATP, should preferentially bind to Hsp90, which is possible because the association constant of the geldanamycin derivatives is greater than that of ATP (refer to Experimental Example 2) . In fact, the geldanamycin derivatives according to the present invention were found to inhibit the expression only of ErbB2, one of the client proteins of Hsp90, without a change in the expression of Hsp90 in the breast cancer cell SK-Br3 (refer to Experimental Example 3 and Table 3) .
Therefore, the geldanamycin derivatives according to the present invention or pharmaceutically acceptable salts thereof can be used as potent Hsp90 inhibitors.
In addition, because Hsp90 plays an important role in the growth and metastasis of cancer cells, by the term "the ability of a material to inhibit Hsp90", it is meant that the material may be used to prevent and treat cancers (Whitesell L. et. al. Proc. Natl. Acad. Sci. USA (1994) 91, 8324-8328; Neckers L. et al. (1999) Invest. New Drugs 17, 361-373; Piper P.W. (2001) Curr. Opin. Investing Drugs 2(11) 1606-1610; Whitesell L. & Lindquist S. L. (2005) Nature Reviews 5, 761-772; Workman P. (2004) Trends in Molecular Medicine 10(2) 47-51) .
Furthermore, the data obtained in assays for cytotoxicity on breast cancer SK-Br3 show that most of the geldanamycin derivatives of the present invention have an IC50 of 50 nM or less, with highly potent cytotoxicity detected in some of them with an IC50 of 10 nM or less (refer to Experimental Example 1 and Table 2) .
Having excellent inhibitory activity against Hsp90 and cytotoxicity on cancer cells, therefore, the geldanamycin derivatives of the present invention or the pharmaceutically acceptable salts thereof can be applied to the prevention and treatment of various cancerous diseases.
Examples of cancerous diseases which can be treated with the geldanamycin derivatives of the present invention include liver cancer, stomach cancer, colon cancer, bone cancer, pancreatic cancer, head and neck cancer, uterine cancer, ovarian cancer, rectal cancer, esophageal cancer, small intestine cancer, periproctic cancer, cancerous Fallopian tube tumor, cancerous endometrioma, cancerous cervical tumors, cancerous vaginal tumors, cancerous vulval tumors, Hodgkin' s disease, prostate cancer, bladder cancer, kidney cancer, ureter cancer, cancerous renal tumors, cancerous tumors of the renal pelvis, tumors of the central nervous system (CNS), and breast cancer.
By the term "the ability of a material to inhibit Hsp90", it is also meant that the material may be used as an antibiotic, an antifungal agent, an antiviral agent, an immunosuppressor, a therapeutic for the treatment of degenerative nerve diseases or an anti-inflammatory agent (Antibiotics, Takahashi A. et al. (2003) PNAS 100(20) 11777-11782; Agbessi S. et al. (2003) Appl. Microbiol. Biotechnol 62, 233-238; Antifungal Agents, Cardenas M. E. et al. (1999) Clinical Microbiology Review 12(4) 583-611; Antiviral Agents, Li Y. et al. (2004) Antimicrobial Agents and Chemotherapy 48(3) 867-872; Immunosuppressors, Owens-Grillo J. et al. (1995) J. Biological Chemistry 270(35) 20479- 20484; Therapeutics for Degenerative nerve diseases, Sittler A. et al. (2001) Human Molecular Genetics 10(12) 1307-1315; Waza M. et al. (2005) Nature medicine 11(10) 1088-1095; Anti-inflammatory Agent, Pittet J. et al. (2005) The Journal of Immunology 174, 384-394; Hsu H. et al. (2006) Molecular Pharmacology, Web pub. JuI 25) . Hence, the geldanamycin derivatives or pharmaceutically acceptable salts thereof can be used as an antibiotic, an antifungal agent, an antiviral agent, an immunosuppressor, a therapeutic for the treatment of degenerative nerve diseases or an anti-inflammatory agent, in accordance with the present invention. A pharmaceutical composition comprising the derivatives of Chemical Formula 1 or pharmaceutically acceptable salts thereof as an active ingredient in accordance with the present invention can be administered either orally or non-orally, and may be provided in general medicine forms . Generally, the derivatives according to the present invention can be formulated in combination with a diluent or excipient, such as a filler, a thickening agent, a binder, a wetting agent, a disintegrant, a surfactant, etc. Solid agents intended for oral administration of the compound of the present invention may be in the form of tablets, pills, powders, granules, capsules, and the like. These solid agents are formulated in combination with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, or gelatine. Besides, a lubricant, such as magnesium stearate, talc and the like, may also be added. Liquid agents intended for oral administration include suspensions, internal use solutions, emulsion, syrups, and the like. In addition to a simple diluent such as water or liquid paraffin, various excipients, such as wetting agents, sweetening agents, aromatics, preservatives, and the like may be contained in the liquid agents for the oral administration of the compound of the present invention. Also, non-oral dosage forms of the compound of the present invention include sterile injections, suspensions, emulsions, freeze-dried agents, and suppositories. For injections, non-aqueous solvents and suspensions made from propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and esters such as ethyl oleate may be used.
The specific dosage level of the derivatives according to the present invention for specific patients may be varied depending on patient's body weight, age, sex, health status, diet, time of administration, method of administration, rate of excretion, severity of disease and other conditions. The pharmaceutical composition may be administered in a single dose or in two or three doses per day, each dose ranging from 1 ~ 250 mg/kg on the basis of the compound of the present invention. It is obvious to those skilled in the art that the geldanamycin derivatives in accordance with the present invention various have biological activities similar to well-known those of geldanamycin and other biological activities inferable there from, as well as the anti-cancer activity described above.
[Mode for Invention] A better understanding of the present invention may be obtained in light of the following examples which are set forth to illustrate, but are not to be construed to limit the present invention.
PREPARATION EXAMPLE 1: Preparation of Starting Material (Chemical Formula 2a)
Figure imgf000025_0001
A carbamoyltransferase gene (gelB) -inactivated strain
(Streptomyces hygroscopicus ACl) of Streptomyces hygroscopicus subsp. duamyceticus was cultured at 280C for 5 days in 3 liters of a yeast extract-malt extract (YEME) medium to accumulate a product from the strain. The culture was extracted twice with ethylacetate and the extract was filtered to remove insoluble materials therefrom. After the filtrate was concentrated, the concentrate was fractionated into ethylacetate and water. The fractions thus obtained were purified by silical gel chromatography using chloroform-methanol . The fractions containing the starting material (2a) were made to pass through a Sephadex LH-20 column and further purified by HPLC [YMC J' sphere ODS-H80, 150 20 mm i.d., methanol-water (0.05% acetic acid) gradient, 10 ml/min] to produce the subject compound as a yellow powder. The fraction was analyzed in comparison with a standard product using HPLC. mp: 80-830C;
[α]D 25=-6.7° (c 0.15, CHCl3); UV(MeOH): -Wdogε) 304(4.24) nm;
ESIMS m/z 520 [M+H] +, 518 [M-H] ";
HRFABMS m/z 542 .2732, C28H41O8NNa 542 .2730 (calculated) .
PREPARATION EXAMPLE 2 : Preparation of Starting Material (Chemical Formula 2b)
Figure imgf000026_0001
Geldanamycin producing strains, including Streptomyces hygroscopicus subsp. duamyceticus, were cultured at 280C for 5 days in 3 liters of yeast extract-malt extract (YEME) media to accumulate products from the strains. The cultures were extracted twice with ethylacetate and the extract was filtered to remove insoluble materials therefrom. After the concentration of the filtrate, the concentrate was fractionated into ethylacetate and water. The fractions thus obtained were purified by silical gel chromatography using chloroform-methanol . The fractions containing the starting material (2b) were made to pass through a Sephadex LH-20 column and further purified by HPLC [YMC J' sphere ODS-H80, 150 20 mm i.d., methanol-water (0.05% acetic acid) gradient, 10 ml/min] to produce the subject compound as a yellow powder. The fraction was analyzed in comparison with a standard product using HPLC. mp: 250-254°;
[α]D 25= +60.4 (c 0.12, CHCl3);
UV(MeOH): λmax(logε) 305(4.10) nm;
ESIMS m/z 561[M+H]+, 559[M-H]"
PREPARATION EXAMPLE 3: Preparation of Starting Material (Chemical
Formula 2c)
Figure imgf000027_0001
A Streptomyces hygroscopicus subsp. duamyceticus strain in which a gene (gel25) sharing high homology with cytochrome 450 is inactivated was cultured at 28°C for 5 days in 3 liters of a yeast extract-malt extract (YEME) medium, which was or was not supplemented with 360 g/1 of sucrose, functioning to retard the growth rate of the strain, so that a product from the strain was accumulated in the medium. The culture was extracted twice with ethylacetate and the extract was filtered to remove insoluble materials therefrom. After the concentration of the filtrate, the concentrate was fractionated into ethylacetate and water. The fractions thus obtained were purified by silical gel chromatography using chloroform-methanol . The fractions containing the starting material (2a) were made to pass through a Sephadex LH-20 column and further purified by HPLC [YMC J' sphere ODS-H80, 150 20 mm i.d., methanol-water (0.05% acetic acid) gradient, 10 ml/min] to produce the subject compound as a yellow powder. The fraction was analyzed in comparison with a standard product using HPLC.
ESIMS: m/z 563[M+H]+, 561 [M-H] " (Schnur, R. C. et al. J. Med. Chem. 1995. 38: 3806-3812).
PREPARATION EXAMPLE 4: Preparation of Starting Material (Chemical Formula 2d)
Figure imgf000028_0001
Trichloroacetyl isocyanate (0.067 mg, 0.57 mmol) was added at 00C to a solution of the starting material prepared in Preparation Example 2 (253.9 mg, 0.45 mmol) in dichloromethane (9.0 ml), and the mixture was stirred for 3 hours. To this mixture were added dichloromethane and excess AI2O3, followed by stirring for 2 hours and filtration. After the filtrate was concentrated, the concentrate was purified using preparative thin layer chromatography (n-hexane:ethylacetate:methanol=6:3:l) to produce the subject compound as a yellow solid (267.6 mg, 98.5%).
1H-NMR (CDCl3, 300 Hz) 8.61 (IH, s, NH), 7.17 (IH, s, 19),
6.56 (IH, t, J = 11.7 Hz, 3), 5.81 (IH, t, J = 10.5 Hz, 4), 5.19 (IH, d, J = 10.2 Hz, 5), 5.81 (IH, s, 9), 4.62 (IH, d, J = 7.5
Hz, 7), 4.40 (IH, d, J = 9.9 Hz, 6), 4.07 (IH, m, 11), 4.03 (3H, s, 17-OCH3), 3.37 (3H, s, 6-OCH3), 3.35 (3H, s, 12-OCH3), 3.31
(IH, m, 12), 2.95 (IH, m, 10), 2.23-2.47 (2H, m, 15), 2.02 (3H, s, 22-CH3), 1.90 (IH, m, 14), 1.77 (3H, s, 23-CH3), 1.51-1.65 (2H, m, 13), 1.14 (3H, d, J = 6.9 Hz, 25), 0.88 (3H, d, J = 7.2 Hz,
24); MS(ESI) m/z 628 (M++Na) , 604 (M-H).
EXAMPLE 1: Preparation of Carbamic acid 9-carbamoyloxy-8 , 14 , 19- trimethoxy-4 , 10,12 , 16-tetramethyl-3,20 ,22-trioxo-2-aza- bicyclo [16.3.1]docosa-1 (21) ,4 ,10 ,18-tetraen-13-yl ester (AC23)
Trichloroacetyl isocyanate (0.01 ml, 0.086 mmol) was added at 0°C to a solution of the starting material prepared in Example 1 (44.5 mg, 0.086 mmol) in dichloromethane (2.0 ml), and the mixture was stirred for 1.5 hours. To this mixture was added dichloromethane and excess Al2θ3, followed by stirring for 2 hours and filtration. After the concentration of the filtrate, the concentrate was purified using preparative thin layer chromatography (n-hexane:ethylacetate:methanol=6:3:l) to produce the subject compound as a yellow solid (35.1 mg, 68%).
1H-NMR (CDCl3, 300 Hz) 8.64 (IH, s, NH), 7.05 (IH, s, 19), 6.52 (IH, t, J = 7.2 Hz, 3), 5.20 (IH, d, J = 10.5 Hz, 9), 4.90 (IH, d, J = 5.4 Hz, 7), 4.78 (2H, brs, NH2), 4.51 (IH, q, J = 2.4 Hz, 6), 4.46 (2H, brs, NH2), 4.03 (3H, s, 17-OCH3), 3.45 (3H, s, 6-OCH3), 3.35 (3H, s, 12-OCH3), 3.29 (2H, m, 11,12), 2.85 (IH, m, 10), 2.26-2.41 (4H, m, 15,4), 1.90 (3H, s, 22-CH3), 1.80 (2H, m, 5), 1.64 (3H, s, 23-CH3), 1.25-1.29 (3H, m, 13,14), 1.10 (3H, d, J = 6.9 Hz, 25), 0.93 (3H, d, J = 6.9 Hz, 24); MS(ESI) m/z 628 (M++Na) , 604 (M-H) .
EXftMPLE 2: Preparation of Carbamic acid 9-carbamoyloxy-19- ethylamino-8 ,14-dimethθ3qf-4 , 10 , 12 ,16-tetramethyl-3,20 ,22-trioxo- 2-aza-bicydo [16.3.1]docosa-1 (21) ,4 , 10,18-tetraen-13-γl ester(AC217)
To a solution of the compound of Example 1 (68.0 mg, 0.11 iranol) in dichloroethylene (5.0 ml) was added ethylamine (0.11 ml, 2 M solution in tetrahydrofuran) . The mixture was stirred overnight, diluted with ethylacetate, and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=20:l) to produce the subject compound as a purple solid (24.3 mg, 36%).
1H-NMR (CDCl3, 300 Hz) 9.28 (IH, s, NH), 7.09 (IH, s, 19), 6.46 (IH, t, J = 6.6 Hz, 3), 5.34 (IH, d, J = 9.6 Hz, 9), 4.96 (IH, d, J = 6.6 Hz, I)1 4.76 (2H, brs, NH2), 4.5 - 4.62 (3H, m, NH2, 6), 3.45-3.53 (3H, m, CH3CH2NH, 11), 3.43 (3H, s, 6-OCH3), 3.39 (3H, s, 12-OCH3), 3.20 (IH, m, 12), 2.75-2.82 (IH, m, 10), 2.32-2.38 (4H, m, 4, 15), 1.90 (3H, s, 22-CH3), 1.74-1.35 (5H, m, 5, 13, 14), 1.54 (3H, s, 23-CH3), 1.30 (3H, m, CH3CH2NH), 1.04 (3H, s, 25), 1.02 (3H, s, 24); MS(ESI) m/z 641 (M++Na) , 617 (M- H).
EXAMPLE 3: Preparation of Carbamic acid 19-allylamino-9- carbamoyloxy-8 , 14-dimethoxy-4 , 10,12 , 16-tetratnethyl-3,20,22- trioxo-2-aza-bicydo[16.3.1]docosa-1 (21) ,4 , 10, 18-tetraen-13-yl ester (AC180)
To a solution of the compound of Example 1 (97.7 ml, 0.17 iranol) in dichloroethylene (4 ml) was added allylamine (0.025 ml, 0.34 mmol) . The mixture was stirred overnight, diluted with ethylacetate, and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=15:l) to produce the subject compound as a purple solid (28.9 mg, 27.0%).
1H-NMR (CDCl3, 300 Hz) 9.24 (IH, s, NH), 7.12 (IH, s, 19), 6.46 (IH, t, J = 6.6 Hz, 3), 5.84-5.97 (IH, m, CH2=CHCH2-), 5.36- 5.50 (3H, m, CH1=CHCH2-, 9), 5.10 (IH, d, J = 7.5 Hz, 7), 4.89 (2H, brs, NH2), 4.71-4.76 (3H, m, NH2, 6), 4.20 (2H, d, J = 4.8 Hz,, CH3CH2NH), 3.61-3.68 (IH, m, 11), 3.57 (3H, s, 6-OCH3), 3.54 (3H, s, 12-OCH3), 3.32 (IH, m, 12), 2.93 (IH, m, 10), 2.40-2.52 (4H, m, 15, 4), 2.04 (3H, s, 22-CH3), 1.68 (3H, s, 23-CH3), 1.88- 1.42 (5H, m, 5, 13, 14) 1.83 (3H, s, 25), 1.61 (3H, s, 24); MS(ESI) m/z 653 (M++Na) , 629 (M-H).
EXAMPLE 4: Preparation of Carbamic acid 9-carbamoyloxy-19- (2- dimethylaταino-ethylamino) -8 , 14-dimethoxy-4 , 10 , 12 , 16-tetramethyl- 3,20, 22-trioxo-2-aza-bicydo [16.3.1] docosa-1 (21) , 4 , 10 , 18-tetraen- 13-yl ester (AC218)
To a solution of the compound of Example 1 (82.5 mg, 0.14 mmol) in dichloroethylene (5.0 ml) was added N, N- dimethylethylenediamine (0.06 ml, 0.54 mmol). The mixture was stirred overnight, diluted with ethylacetate, and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and dried. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=20:l) to produce the subject compound as a purple solid (32.6 mg, 35%). 1H-NMR (CDCl3, 300 Hz) 9.27 (IH, S, NH), 7.07 (IH, s, 19),
6.74 (IH, t, J = 4.8 Hz, NH), 6.45 (IH, t, J = 6.6 Hz, 3), 5.34
(IH, d, J = 9.6 Hz, 9), 4.95 (IH, d, J = 7.2 Hz, 7), 4.83 (2H, brs, NH2), 4.70 (2H, brs, NH2), 4.59 (IH, m, 6), 3.46-3.56 (3H, m, 11, (CH3J2NCH2CH2NH), 3.42 (3H, s, 6-OCH3), 3.39 (3H, s, 12- OCH3), 3.18 (IH, m, 12), 2.78 (IH, m, 10), 2.53-2.70 (4H, m, 4, (CHs)2NCH2CH2NH), 2.31 (8H, m, (CH3J2N, 15), 1.89 (3H, s, 22-CH3), 1.74-1. 32 (5H, m, 5, 13, 14 ) , 1 . 53 (3H, s , 23-CH3) , 1 . 01-1. 04 ( 6H, m, 24, 25) ; MS (ESI) m/z 684 (M++H) , 660 (M-H) .
EXAMPLE 5: Preparation of Carbamic acid 9-carbamoyloxy-19- (2- diethylamino-ethylamino) -8 , 14-dimethoxy-4 ,10 ,12 , 16-tetramethyl-
3,20,22-trioxo-2-aza-bicyclo[16.3.1]docosa-1 (21) ,4,10 , 18-tetraen- 13-yl ester (AC222)
To a solution of the compound of Example 1 (114.0 mg, 0.19 mmol) in dichloroethylene (3.0 ml) was added N, N- dimethylethylenediamine (0.11 ml, 0.75 mmol). The mixture was stirred overnight, diluted with ethylacetate, and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane : methanol=20:l) to produce the subject compound as a purple solid (42 mg, 32%) .
1H-NMR (CDCl3, 300 Hz) 9.27 (IH, s, NH), 7.05 (IH, s, 19), 6.93 (IH, t, J = 4.8 Hz, NH), 6.45 (IH, t, J = 6.6 Hz, 3), 5.34 (IH, d, J = 9.0 Hz, 9), 4.94 (IH, d, J = 7.2 Hz, 7), 4.81 (2H, brs, NH2), 4.67 (2H, brs, NH2), 4.58 (IH, q, J = 2.4 Hz, 6), 3.49-3.56 (3H, m, 11, NHCH2-), 3.42 (3H, S, 6-OCH3), 3.39 (3H, s, 12-OCH3), 3.17 (IH, m, 12), 2.62-2.84 (7H, m, NHCH2CH2N (CH2CHs)2, 10), 2.33 (4H, m, 4, 15), 1.89 (3H, s, 22-CH3), 1.35-1.76 (5H, m, 5, 13, 14), 1.52 (3H, s, 23-CH3), 1.01-1.08 (12H, m, N(CH2CHj)2, 24, 25); MS(ESI) m/z 712 (M++Na) , 688 (M-H). EXAMPLE 6: Preparation of 3-Oxo-butyric acid 8 , 14 , 19-trimethoxy- 4,10 ,12 , 16-tetxamethyl-3,20 ,22-trioxo-13- (3-oxo-butyryloxγ) -2- aza-bicyσlo[16.3.1]docosa-1 (21) ,4 , 10 ,18-tetraen-9-yl ester (AC48)
Triethylamine (0.0012 ml, 0.0087 mmol) was slowly added at room temperature to a mixture comprising a catalytically effective amount of 4-dimethylamino-pyridine in tetrahydrofuran (1 ml), the compound of Preparation Example 1 (41.2 mg, 0.079 mmol), and diketene (0.0067 ml, 0.087 mmol). The reaction mixture was stirred overnight and concentrated. The concentrate was purified using preparative thin layer chromatography (n- hexane:ethylacetate:methanol=6: 3: 1) to produce the subject compound as a yellow solid (7.6 mg, 16%). 1H-NMR (CDCl3, 300 Hz) 8.69 (IH, s, NH), 7.03 (IH, s, 19), 6.42 (IH, t, J = 6.6 Hz, 3), 5.28 (IH, d, J = 9.9 Hz, 9), 5.10 (IH, d, J = 7.5 Hz, I)1 4.75 (IH, q, J = 2.7 Hz, 6), 4.12 (3H, s, 17-OCH3), 3.47 (2H, s, COCH2CO), 3.41 (3H, S, 6-OCH3), 3.37 (3H, s, 12-OCH3), 3.35 (2H, s, COCH2CO), 3.26 (2H, m, 11,12), 2.87 (IH, m, 10), 2.35-2.41 (4H, m, 15,4), 2.27 (3H, s, COCH3), 2.20 (3H, s, COCH3), 1.88 (3H, s, 22-CH3), 1.59 (3H, s, 23-CH3), 1.44 (2H, m, 5), 1.23-1.33 (3H, m, 13,14), 1.10 (3H, d, J = 6.9 Hz, 25), 0.97 (3H, d, J = 6.6 Hz, 24); MS(ESI) m/z 710 (M++Na) , 686 (M-H) .
EXAMPLE 7: Preparation of Methyl-carbamiσ acid 8,14-dimethoxy- 4 ,10, 12 , lβ-tetramethyl-lθ-methylamino-lS-methylcarbamoyloxy-
3,20,22-trioxo-2-aza-bicydo [16.3.1]docosa-1 (21) ,4 ,10 , 18-tetraen-
9-yl ester (AC130)
To a solution of the compound of Preparation Example 1 (40.0 mg, 0.077 mmol) in dichloromethane (1.0 ml) was added 1,1'- carbonyldiimidazole (31.2 mg, 0.19 mmol), and the mixture was stirred overnight. Methylamine (0.014 ml, 2 M solution in tetrahydrofuran) was added before stirring for an additional one hour and then the mixture was concentrated. The concentrate was purified using preparative thin layer chromatography (n- hexane:ethylacetate:methanol=6:3:l) to produce the subject compound as a purple solid (7.4 mg, 15%).
1H-NMR (CDCl3, 300 Hz) 9.44 (IH, s, NH), 7.11 (IH, s, 19), 6.54 (IH, m, 3), 5.30 (IH, d, J = 9.3 Hz, 9), 4.95 (IH, d, J = 7.5 Hz, 7), 4.62 (IH, m, 6), 3.52 (IH, m, 11), 3.36 (6H, s, 6- OCH3, NHCH3), 3.34 (IH, m, 12), 3.16 (3H, s, 12-OCH3), 2.71-2.74 (7H, m, CONHCH3, 10), 2.35 - 2.41 (4H, m, 15,4), 2.00 (3H, s, 22- CH3), 1.86 (3H, s, 23-CH3), 1.45-1.78 (5H, m, 5,13,14), 1.21 (3H, t, J = 6.9 Hz, 25), 1.00 (3H, t, J = 6.6 Hz, 24); MS(ESI) 655 (M++H) , 631 (M-H) .
EXAMPLE 8: Preparation of Carbamic acid 19-allylatnino-9- carbamoyloxy-8 , 14-dimethoxy-4, 10 ,12 , 16-tetramethyl-3,20 ,22- trioxo-2-aza-bicyclo [16.3.1]docosa-1 (21) ,4 , 6,10 , 18-pentaen-13-yl ester (ACC199) To a solution of the compound of Chemical Formula 2d (42.3 mg, 0.07 mmol) in dichloroethylene (3.0 ml) was added N,N- dimethylethylenediamine (0.036 mg, 0.26 mmol), followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=10:l) to produce the subject compound as a purple solid (43.5 mg, 80%).
1H-NMR (CDCl3, 300 Hz) 9.23 (IH, s, NH), 7.15 (IH, s, 19), 6.54 (IH, ps t, J = 11.7 Hz, 3), 5.90 (2H, m, 4, =CH) , 5.24-5.33 (2H, m, 5, 9), 4.80 (3H, m, 7, CH2=CHCH2NH), 4.48 (IH, d, J = 8.1 Hz, 6), 4.43 (2H, brs, NH2), 4.09 (2H, d, J = 5.4 Hz, =CHCH2NH) , 3.50 (IH, m, 11), 3.36 (3H, s, 6-OCH3), 3.24-3.38 (4H, s, 12-OCH3, 12), 2.87-2.94 (IH, m, 10), 2.56 - 2.63 (IH, m, 15 ), 2.27-2.34 (IH, m, 15 ), 2.01 (3H, s, 22-CH3), 1.81-1.86 (IH, m, 14), 1.74 (3H, s, 23-CH3), 1.52-1.61 (2H, m, 13), 1.03 (3H, d, J = 6.6 Hz, 25), 0.97 (3H, d, J = 7.5 Hz, 24); MS(ESI) m/z 651 (M++Na) , 627 (M-H) .
EXAMPLE 9: Preparation of Carbamic acid 9-carbamoyloxy-19- (2- dimethylamino-ethylamino) -8 , 14-dimethoxy-4, 10,12 ,16-tetramethyl- 3,20,22-trioxo-2-aza-bicyσlo[16.3.1]docosa-l(21) ,4,6,10,18- pentaen-13-yl ester (AC219) To a solution of the compound of Chemical Formula 2d 66.5 mg, 0.11 mmol) in dichloroethylene (5.0 ml) was added N, N- dimethylethylenediamine (0.036 ml, 0.33 mmol), followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=20: 1) to produce the subject compound as a purple solid (21.7 mg, 30%) . 1H-NMR (CD3OD + CDCl3, 300 Hz) 7.24 (IH, brd, J = 11.4 Hz,
3), 6.98 (IH, s, 19), 6.56 (IH, ps t, J = 11.4 Hz, 4), 5.84 (IH, ps t, J = 10.5 Hz, 5), 5.30 (2H, m, 9, I)1 4.59 (IH, d, J = 7.8
Hz, 6), 3.68 (2H, m, (CHs)2NCH2CH2NH), 3.60 (2H, m, 11, 12), 3.30
(6H, s, 6-OCH3, 12-OCH3), 2.83-2.94 (3H, m, 10, (CH3) 2NCHgCH2NH) , 2.50 (6H, s, (CH3)2N), 2.23-2.00 (2H, m, 15), 1.98 (3H, s, 22- CH3), 1.75-1.88 (IH, m, 14), 1.69 (3H, s, 23-CH3), 1.31-1.63 (2H, m, 13), 1.02 (3H, d, J = 6.9 Hz, 25), 0.97 (3H, d, J = 6.6 Hz, 24); MS(ESI) m/z 682 (M++H) , 658 (M-H).
EXAMPLE 10: Preparation of Carbamic acid 9-carbamoyloxy-19- (2- diβthylamino-ethylamino) -8 , 14-dimethoxy-4 ,10 , 12 , 16-tetramethyl- 3,20 ,22-trioxo-2-aza-bicydo [16.3.1]docosa-1 (21) ,4 , 6, 10 , 18- pentaen-13-yl ester (AC221)
To a solution of the compound of Chemical Formula 2d (76.3 mg, 0.14 mmol) in dichloroethylene (5.0 ml) was added N,N- dimethylethylenediaraine (0.072 ml, 0.51 mmol), followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=20:l) to produce the subject compound as a purple solid (10.4 mg, 12%).
1H-NMR (CDC13, 300 Hz) 9.22 (IH, s, NH), 7.07 (IH, s, 19), 6.53 (IH, ps t, J = 11.4 Hz, 3), 5.82 (IH, t, J = 10.2 Hz, 4), 5.30 (2H, m, 5, 9), 4.80 (3H, brs, 7, NH2), 4.46 (IH, d, J = 7.8 Hz, 6), 3.59-3.76 (3H, m, 11, NHCH2-), 3.48 (IH, m, 12), 3.35 (3H, s, 12-OCH3), 3.34 (3H, s, 6-OCH3), 2.76-2.89 (7H, m, 10, NHCH2CH2N (CH2CH3) 2) , 2.31- 2.34 (2H, m, 15), 2.00 (3H, s, 22-CH3), 1.87 (IH, m, 14), 1.74 (3H, s, 23-CH3), 1.36-1.60 (2H, m, 13), 1.17-1.19 (6H, m, N(CH2CH3J2), 1.05 (3H, d, J = 6.0 Hz, 25), 0.95 (3H, d, J = 6.0 Hz, 24); MS(ESI) m/z 710 (M++H) , 686 (M-H).
EXMAPLE 11: Preparation of Carbamic acid 9-carbamoyloxy-8,14- dimethoxy-4 , 10 , 12 , 16-tetramethyl-3,20 ,22-trioxo-19- (2-pγrrolidin- 1-yl-ethylamino) -2-aza-bicydo [16.3.1]docosa-1 (21) ,4 , 6,10, 18- pentaen-13-yl ester (AC225)
To a solution of the compound of Chemical Formula 2d (42.9 mg, 0.071 mmol) in dichloroethylene (5.0 ml) was added l-(2- aminoethyl) pyrrolidine (0.071 ml, 0.57 mmol), followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=20: 1) to produce the subject compound as a purple solid (17 mg, 35 %) .
1H-NMR (CDC13, 400 Hz) 9.23 (IH, s, NH), 7.08 (IH, s, 19), 6.69 (IH, brs, 3), 6.53 (IH, ps t, J = 11.4 Hz, 4), 5.82 (IH, t, J = 10.2 Hz, 5), 5.30 (2H, m, 9, 7), 4.82 (2H, brs, NH2), 4.47 (IH, d, J = 8.4 Hz, 6), 3.67 (2H, m, NHCH2-), 3.48 (2H, m, 11, 12), 3.46 (6H, s, 6-OCH3, 12-OCH3), 2.60-2.90 (7H, m, NHCH2CH2-, piperidine-H, 10), 2.02-2.40 (2H, m, 15), 2.00 (3H, s, 22-CH3), 1.79-1.89 (5H, m, piperidine-H, 14), 1.73 (3H, s, 23-CH3), 1.42- 1.68 (2H, m, 13), 1.08 (3H, d, J = 6.9 Hz, 25), 0.94 (3H, d, J = 6.6 Hz, 24); MS(ESI) m/z 686 (M++H) , 684 (M-H) .
EXAMPLE 12: Preparation of Carbamic acid 19-ethylamino-13- hydroxy-8 , 14-dimethoxγ-4 , 10 , 12 , 16-tetramethγl-3 , 20 , 22-trioxo-2- aza-bicydo [16.3.1] docosa-1 (21) , 4 , 10 , 18-tetraen-9-yl ester
(AC216)
To a solution of the compound of Preparation Example 3
(71.6 mg, 0.13 mmol) in dichloroethylene (5.0 ml) was added ethylamine (0.125 ml, 2M solution in tetrahydrofuran) , followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=20:l) to produce the subject compound as a purple solid (45.2 mg, 62%) . 1H-NMR (CDCl3, 400 Hz) 9.30 (IH, S, NH), 7.14 (IH, s, 19), 6.23-6.25 (2H, m, 3, NH), 5.79 (IH, d, J = 9.6 Hz, 9), 5.20 (IH, d, J = 5.2 Hz, 7), 4.68 (2H, brs, NH2), 3.41 (3H, s, 6-OCH3), 3.37 (3H, s, 12-OCH3), 3.33-3.62 (5H, m, 6, 11, 12, CH3CH2NH), 2.72 (IH, m, 10), 2.41 (4H, m, 4, 15), 1.91 (3H, s, 22-CH3), 1.64-1.76 (5H, m, 5, 13, 14), 1.68 (3H, s, 23-CH3) , 1.34 (3H, t, J = 6.8 Hz, CH3CH2NH), 1.02 (IH, d, J = 7.2 Hz, 25), 0.97 (3H, d, J= 6.8 Hz, 24); MS(ESI) m/z 598 (M+H-Na), 574 (M-H).
EXAMPLE 13: Preparation of Carbamic acid 19-allylaτnino-13- hydroxy-8 ,14-dimethoxy-4 , 10 , 12 , 16-tetramethyl-3,20 ,22-trioxo-2- aza-bicydo[16.3.1]docosa-1 (21) ,4, 10 , 18—tetraen-9-yl ester (AC220)
To a solution of the compound of Preparation Example 3 (80.4 mg, 0.14 mmol) in dichloroethylene (5.0 ml) was added allylamine (0.021 ml, 0.29 mmol), followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=20:l) to produce the subject compound as a purple solid (44.9 mg, 55%).
1H-NMR (CDCl3, 300 Hz) 9.23 (IH, s, NH), 7.12 (IH, s, 19),
6.39 (IH, t, J = 6.0 Hz, NH), 6.21 (IH, m, 3), 5.90 (IH, m, =CH) , 5.75 (IH, d, J = 9.0 Hz, 9), 5.27 (2H, m, CH2=), 5.15 (IH, d, J = 5.7 Hz, I)1 4.91 (2H, brs, NH2), 4.11 (2H, t, J = 6.3 Hz, =CHCH2NH) , 3.57 (IH, m, 6), 3.28-3.44 (2H, m, 11, 12), 3.38 (3H, s, 6-OCH3), 3.34 (3H, s, 12-OCH3), 2.62-2.67 (IH, m, 10), 2.26-
2.40 (4H, m, 4, 15), 1.88 (3H, s, 22-CH3), 1.68 (5H, m, 5, 13, 14), 1.65 (3H, s, 23-CH3), 0.95-0.99 (6H, m, 24, 25); MS(ESI) m/z 610 (M++Na), 586 (M-H).
EXAMPLE 14 : Preparation of Carbamic acid 19- (2-dimethylamino- ethylamino) -13-hydroxy-8,14-dimethoxy-4,10,12 ,16-tetramethyl- 3,20,22-trioxo-2-aza-bicyclo[16.3.1]docosa-1 (21) ,4 ,10 , 18-tetraen- 9-yl ester (AC196)
To a solution of the compound of Preparation Example 3 (85.4 mg, 0.15 mmol) in dichloroethylene (4.0 ml) was added N,N- dimethylethylenediamine (0.033 ml, 0.30 mmol), followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=20: 1) to produce the subject compound as a purple solid (18.9 mg, 20%).
1H-NMR (CDCl3, 300 Hz) 9.26 (IH, s, NH), 7.09 (IH, s, 19), 7.00 (IH, brs, NH), 6.23 (IH, t, J = 6.6 Hz 3), 5.78 (IH, d, J = 9.3 Hz, 9), 5.17 (IH, d, J = 5.4 Hz, 7), 4.80 (2H, brs, NH2), 3.82 (IH, m, 6), 3.30-3.72 (4H, m, 11,12, (CHs)2NCH2CH1NH), 3.39 (3H, s, 6-OCH3), 3.335 (3H, s, 12-OCH3), 2.66-2.75 (3H, m, 10 , (CH3J2NCH2CH2NH-), 2.34-2.41 (1OH, s, (CH3) 2N, 4, 15), 1.89 (3H, s, 22-CH3), 1.72-1.69 (5H, m, 5, 13, 14), 1.67 (3H, s, 23-CH3), 0.95-1.00 (6H, m, 24, 25); MS(ESI) m/z 619 (M++H) , 617 (M-H).
EXAMPLE 15: Preparation of Carbamic acid 19- (2-diethylamino- ethylamino) -13-hydroxy-8, 14-dimethoxy-4 , 10 , 12 , 16-tetramethyl-
3,20,22-trioxo-2-aza-bicyclo[16.3.1]docosa-1 (21) ,4 , 10 , 18-tetraen- 9-yl ester (AC223)
To a solution of the compound of Preparation Example 3 (80.0 mg, 0.14 iranol) in dichloroethylene (4.0 ml) was added N,N- dimethylethylenediamine(0.04 ml, 0.29 mmol) , followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=20:l) to produce the subject compound as a purple solid (46,8 mg, 52%).
1H-NMR (CDCl3, 300 Hz) 9.24 (IH, s, NH), 7.18 (IH, t, J =
5.1 Hz, NH), 7.05 (IH, s, 19), 6.22 (IH, t, J = 6.6 Hz, 3), 5.75 (IH, d, J = 9.0 Hz, 9), 5.15 (IH, d, J = 5.7 Hz, 7), 4.92 (2H, brs, NH2), 3.71 (2H, m, NHCH2-), 3.58-3.28 (3H, m, 6, 11, 12), 3.38 (3H, s, 6-OCH3), 3.34 (3H, s, 12-OCH3), 2.62-2.84 (7H, m, NHCH2CHgN (CH2CH3) 2, 10), 2.37 (4H, m, 4, 15), 1.88 (3H, s, 22-CH3), 1.70 (5H, m, 5, 13, 14), 1.65 (3H, s, 23-CH3), 1.12 (6H, m, N(CH2CHg)2), 0.95-0.99 (6H, m, 24, 25); MS(ESI) m/z 647 (M++H) , 645 (M-H) .
EXAMPLE 16: Preparation of Carbamic acid 13-hydroxy-8,14- dimethoxy-4 , 10 , 12 , 16-tetramethyl-3,20 ,22-trioxo-19- (2-pyrrolidin- 1-yl-ethylamino) -2-aza-bicydo [16.3.1]docosa-1 (21) ,4 ,10 , 18- tetraen-9-yl ester
To a solution of the compound of Preparation Example 3 (77.8 mg, 0.14 mmol) in dichloroethylene (3.0 ml) was added l-(2- aminoethyl)pyrrolidine (0.035 ml, 0.28 mmol), followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=10:l) to produce the subject compound as a purple solid (10.9 mg, 12%).
1H-NMR (CDCl3, 300 Hz) 9.21 (IH, S, NH), 7.07 (IH, s, 19), 6.97 (IH, brs, NH), 6.23 (IH, t, J = 6.6 Hz, 3), 5.77 (IH, d, J =
9.3 Hz, 9), 5.17 (IH, d, J = 4.8 Hz, 7), 4.82 (2H, brs, NH2), 4.743 (IH, brs, OH), 3.56-3.85 (4H, m, NHCH2CH2N, 6, 11), 3.45 (IH, m, 12), 3.39 (3H, s, 6-OCH3), 3.35 (3H, s, 12-OCH3), 2.91-
3.04 (6H, m, NHCH2CH2N, piperidine-H) , 2.63 - 2.68 (IH, m, 10), 2.37 (4H, m, 4, 15), 2.02-2.06 (4H, m, piperidine-H) , 1.89 (3H, s, 22- CH3), 1.67-1.72 (7H, s, 23-CH3, , 5, 13, 14),, 0.98-1.00 (6H, m, 24, 25); MS(ESI) m/z 667 (M++Na) , 643 (M-H).
EXAMPLE 17: Preparation of Carbamic acid 13-hydroxy-8,14- dimethoxy-4,10,12 ,16-tetramethyl-19- (2-morpholin-4-yl- βthylamino) -3,20,22-trioxo-2-aza-bicydo [16.3.1]docosa- 1 (21) ,4 ,10,18-tetraen-9-yl ester
To a solution of the compound of Preparation Example 3 (78.6 mg, 0.14 ramol) in dichloroethylene (4.0 ml) was added 4- (2- aminoethyl)morpholine (0.04 ml, 0.28 mmol), followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=18:l) to produce the subject compound as a purple solid (50.7 mg, 55%) .
1H-NMR (CDCl3, 300 Hz) 9.25 (IH, s, NH), 7.08 (IH, s, 19), 7.06 (IH, brs, NH), 6.23 (IH, t, J = 6.6 Hz, 3), 5.77 (IH, d, J = 9.6 Hz, 9), 5.16 (IH, d, J = 5.4 Hz, 7), 4.88 (2H, brs, NH2), 3.42-3.76 (9H, m, NHCH2CH2-, morpholine-H, 6, 11, 12), 3.38 (3H, s, 6-OCH3), 3.34 (3H, s, 12-OCH3), 2.51-2.74 (7H, m, NHCH2CH2-, morpholine-H, 10), 2.36 - 2.39 (4H, m, 4, 15), 1.88 (3H, s, 22- CH3), 1.71 (5H, m, 5, 13, 14), 1.66 (3H, s, 23-CH3),, 0.94-0.99 (6H, m, 24, 25); MS(ESI) m/z 683 (M++Na) , 659 (M-H). EXAMPLE 18: Preparation of Carbamic acid 13-hydroxy-19- (3- imidazol-1-yl-propylamino) -8 , 14-dimethoxy-4 , 10 , 12 , 16-tetramethyl- 3,20,22-trioxo-2-aza-bicydo [16.3.1] docosa-1 (21) , 4 , 10 , 18-tetraen- 9-yl ester
To a solution of the compound of Preparation Example 3 (72.8 mg, 0.13 iranol) in dichloroethylene (4.0 ml) was added l-(3- aminopropyl) imidazole (0.04 ml, 0.28 mmol) , followed by stirring the mixture overnight. It was diluted with ethylacetate and washed with an aqueous bicarbonate solution and brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified using preparative thin layer chromatography (dichloromethane:methanol=18:l) to produce the subject compound as a purple solid (45.8 mg, 54%).
1H-NMR (CDC13,3OO Hz) 9.19 (IH, s, NH), 7.09 (IH, s, 19), 6.25 (IH, t, J = 6.3 Hz, N=CH-N), 6.19 (IH, t, J = 6.9 Hz, 3), 5.72 (IH, d, J = 9.3 Hz, 9), 5.12 (IH, d, J = 4.8 Hz, 7), 4.94 (2H, brs, NH2), 4.11 (2H, m, NCH=CHN), 3.41-3.62 (7H, m, NHCH2CH2CH2-, 6, 11, 12), 3.37 (3H, s, 6-OCH3), 3.33 (3H, s, 12- OCH3), 2.68 (IH, m, 10), 2.34 (2H, m, NHCH2CH2CH2-), 2.15 (4H, m, 4, 15), 1.87 (3H, s, 22- CH3), 1.53-1.68 (8H, s, 23-CH3, 5, 13, 14), 0.96 (3H, d, J = 6.6 Hz, 24), 0.85 (3H, d, J = 5.7 Hz, 25); MS(ESI) m/z 678 (M++Na) , 654 (M-H).
The compounds prepared in Examples 1 to 18 are summarized Table 1, below.
TABLE 1
Figure imgf000046_0001
Figure imgf000047_0001
EXPERIMENTAL EXAMPLE 1: Assay for Affinity for Hsp90
1-1. Purification and Isolation of ATP-Binding Site Domain of Hsp90
The ATP-binding site domain of Hsp90 was isolated and purified as follows.
PCR was performed with a set of primers (forward primer with an Ndel site: 5'-CCA TAT GCC TGA GGA AAC CCA GAC CC-3' and backward primer with an Sail site: 5'-GTC GAC CTT TTC TTC AGC CTC ATC ATC GC-3' ) to amplify an N-terminal region comprising the ATP-binding site domain of Hsp90, and the PCR product was cloned into a pET-22b(+) vector (FIG. 1) which was then transformed into E. coli BL21(DE3). The protein of interest was produced through the overexpression of the gene. In this regard, first, the E. coli carrying the plasmid was cultured for about 16 hours in 5 ml of an LB (Luria-Bertani) broth containing ampicillin in an amount of 50 μg/ml. After 50-fold dilution with 200 ml of a fresh LB broth, the culture was incubated for an additional 2~3 hours . When the OD (optical density) of the culture reached about 0.4~0.8, as measured at 600 nm using a UV spectrophotometer, isopropyl β-D-thioglucopyranoside (IPTG) was added at a final concentration of 1 mM to induce overexpression, followed by incubation at 370C for an additional 4 hours. After being collected by centrifugation (6000 rpm, 10 min) , the cells were suspended in 10 ml of a 100 mM lysis buffer (100 mM NaH2PO4 pH 7.8, 10 mM Tris-HCl, 0.2 mM PMSF, 0.2 mM β-mercaptoethanol) and lyzed through sonication. After the removal of cell debris by centrifugation, the expression of the protein of interest was identified using SDS-PAGE.
The lysate supernatant was mixed at room temperature for 15 ~ 60 min with 1 ml of Ni-NTA resins and gently shaken. The lysate-resin was carefully loaded onto a column which was then treated twice with 4 ml of a wash buffer (100 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) and finally four times with 0.5 ml of an elution buffer (100 mM NaH2PO4, 300 itiM NaCl, 200 iriM imidazole, pH 8.0). The fractions thus eluted were subjected to SDS-PAGE, and the results are shown in FIG. 2.
As seen in FIG. 2, a neat protein band was detected at 28 kDa, which corresponds to the molecular weight of the ATP-binding site domain of Hsp90.
1-2. Binding Force to Hsp90 Protein
The direct binding force between Hsp90 and the compound of Chemical Formula 1 in accordance with the present invention was measured as follows.
1) Experiment Principle and Apparatus
BIACORE® is an instrument adapted for measuring protein- protein interaction and binding affinity on a sensor chip, based on Surface Plasmon Resonance (SPR) , an optical phenomenon that enables detection of unlabeled interactants in real time. Hence, all experiments were performed with BIACORE® 3000 using a CM5 sensor chip and an HBS-P buffer. A CM5 chip, one of the most widely used biosensor chips, is coated with dextran with negative charges on the carboxyl groups thereof. Dextran is a straight chain consisting of glucose units and shows almost no nonspecific binding to biomaterials . When the pH of the buffer is lower than the pi of a protein to be immobilized, the negative charge of the carboxylic group on the surface of the chip causes the positively charged protein to be adsorbed to the chip. The surface on which ligands are immobilized is readily activated with N-hydroxysuccinimide (NHS) and N-ethyl-N' -
(dimethylaminopropyl) carbodiimide (EDC) . Under general conditions, about 40% of the carboxyl groups are converted into N-hydroxysuccinimide ester (NHS-ester) , which is highly reactive.
The N-hydroxysuccinimide-ester can form bonds with primary amino groups of proteins or other biomaterials . Preferable is a buffer having a low pH because it allows samples to readily reach the surface of the sensor chip.
2) Measurement of binding affinity
For use in immobilizing the N-terminal Hsp90 protein purified in Experimental Example 1-1 on a CM5 chip, HBS-P buffer, commercially available from BIACORE, was identified to provide optimal conditions at pH 4.5, as measured by a preconcentration test. Samples were immobilized to a No. 4 flow cell on the CM5 biosensor chip using standard amine coupling chemistry with a flow rate of 5 μl/min in HBS-P running buffer. For this, the chip surface was activated with an injection of 50 μl of N-ethyl- N' - (dimethylaminopropyl) carbodiimide) /N-hydroxysuccinimide into the flow cell, followed by injecting 100 μl of a dilution of 60 μl of 1 mg/ml N-terminal Hsp90 protein in 80 μl of 10 mM sodium acetate buffer (pH 4.5) to immobilize the protein. Excess protein was removed with an injection of 5 μl of 50 mM sodium hydroxide before the injection of 50 μl of IM ethanolamine to block the remaining active NHS-ester. Therefore, the immobilization of the N-terminal Hsp90 protein of 4230 RU was achieved. As a control, BSA was immobilized to a No. 3 flow cell in the same manner as described above.
In order to examine the binding kinetics of the materials competing with each other for the ATP-binding site of the N- terminal Hsp90 protein, geldanaitiycin (Preparation Example 2) and the compounds of Chemical Formula 1 were dissolved in ethanol to give a 10 mM solution which was then diluted with 2% ethanol- supplemented HBS-P buffer to a series of concentrations of 5,000, 2,500, 1,250, 625, 312 and 156 nM before injection. Kinetic studies were performed on triplicate injection of 30 μl of each sample with a flow rate of 30 μl/rain in buffer with 1 min and 2 min set for association time and dissociation time, respectively. A sensorgram was given as a mean value set by subtracting the value of the No. 3 flow cell from that of the No. 4 flow cell upon the triplicate injection. The sensorgrams were corrected by subtracting the control sensorgram, the mean obtained with the running buffer in the same manner, from the mean sensorgram of each sample. The corrected sensorgrams were used to give association constants for samples (Ka (1/ms) means numbers of the association of 1 molar compound with Hsp90 per sec) , dissociation constants for samples (Kd (1/s) means numbers of the dissociation of the complex into individuals per sec) , equilibrium dissociation constants (KD (Kd/ka) refers to dissociation tendency, with higher values corresponding to low affinity) , and the chi-square values (Chi2; a standard statistical measure of closeness of fit; values below 10 are acceptable) , and the results are summarized in Table 2, below.
TABLE 2
Figure imgf000052_0001
* ND (not detected)
As seen in Table 2, most of the geldanamycin derivatives according to the present invention were measured to have association constant (Kd) values far greater than dissociation constant (Kd) values or the association constant value of ATP for Hsp90. From these data, it is speculated that the geldanamycin derivatives according to the present invention have such high affinity for Hsp90 as to bind to Hsp90, in preference to ATP, thus inhibiting the chaperone activity of Hsp90.
EXPERIMENTAL EXAMPLE 2: Inhibitory Effect of Geldanamycin Derivatives on the Expression of the Hsp90 client protein ErbB2
An experiment was performed with 17-allyl amino geldanamycin, a geldanamycin derivative, to inhibit ErbB2 (kinase, involved in cancer development) , a client protein of Hsp90, as follows.
After the treatment of ErbB2-overexpression cells with 17- allyl amino geldanamycin, ErbB2 expression levels were monitored over time. For this, first, SK-Br3, a human breast cancer strain, was cultured at 370C for 24 hours in a 5% CO2 atmosphere and than treated with a 1 μM 17-allyl amino geldanamycin solution in DMSO, followed by incubation for the same time period. After collection by centrifugation, the cell pellet was homogenized in a lysis buffer (50 mM Tris buffer pH 7.6, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, l%(v/v) protease inhibitor mixture (Sigma #P8340) ) and lyzed by sonication. The lysate was subjected to protein analysis using a BCA method. 50 μg of each of the protein samples thus obtained was loaded on SDS-PAGE, followed by immunoblotting against ErbB2 and Hsp90. The results are shown in FIG. 3.
As is understood from the data of FIG. 3, ErbB2 begun to decrease in expression from 4 hours after the treatment with 1 μM
17-allyl amino geldanamycin, and was hardly detected at all 8 hours after the treatment. In contrast, the expression level of
Hsp90 was observed to experience no change for 8 hours after the treatment with 17-allyl amino geldanamycin. From these observations, it is speculated that the geldanamycin derivatives according to the present invention directly inhibit the activity of Hsp90 by binding to Hsp90, which results in a decrease in the expression of ErbB2, a client protein of Hsp90.
EXPERIMENTAL EXAMPLE 3: In Vivo Assay for Anticancer Activity
The compounds represented by Chemical Formula 1 in accordance with the present invention were assayed for cytotoxicity against cancer cells as follows. SK-Br3, a human breast cancer cell line in which the Hsp90 client protein ErbB2 (kinase, involved in cancer development) is overexpressed, is widely used for the assay of conventional geldanamycin derivatives for anticancer activity. SK-Br3 cells were plated at a density of IxIO4 cells per well into 96-well plates, incubated at 370C for 24 hours in a 5% CO2 atmosphere, and treated with 100, 10, 1, 0.1, 0.01, 0.001, 0.0001, 0.00001, and 0 μM of each sample in DMSO, followed by incubation for 72 hours under the same conditions . Incubation with MTT reagent at 37°C for 4 hours formed formazan within cells. Then, the cells were incubated overnight with a lysis buffer at 370C, followed by measuring absorbance at 570 nm/650 nm using a UV spectrophotometer to calculate IC50, and the results are given in Table 3, below.
TABLE 3
Figure imgf000055_0001
As shown in Table 3, most of the compounds of Chemical Formula 1 have IC50 values less than 50 nM for the breast cancer cell line SK-Br3. Particularly, the compounds of Examples 5, 11 and 15 are lower in IC50 value than the conventional geldanamycin derivative 17-DMAG. From these data, it is understood that the geldanamycin derivatives of Chemical Formula 1 in accordance with the present invention bind to the ATP-binding site of Hsp90 to inhibit the expression and stability of the client proteins thereof, involved in cancer development, such as ErbB2, thus exerting cytotoxicity on cancer cells.
The compounds of the present invention are formulated as follows .
FORMULATION EXAMPLE 1: Preparation of Powder
Derivative of Chemical Formula 1 2g
Lactose Ig The above ingredients were mixed and loaded into an airtight sac to produce powder.
FORMULATION EXAMPLE 2: Preparation of Tablet
Derivative of Chemical Formula 1 lOOmg
Corn Starch lOOmg
Lactose lOOmg
Mg Stearate 2mg
These ingredients were mixed and prepared into tablets using a typical tabletting method.
FORMULATION EXAMPLE 3: Preparation of Capsule
Derivative of Chemical Formula 1 lOOmg Corn Starch lOOmg
Lactose lOOmg Mg Stearate 2mg
These ingredients were mixed and loaded into gelatin capsules according to a typical method to produce capsules .
[industrial Applicability] With inhibitory activity against the chaperone protein Hsp90, which plays an important role in the growth and metastasis of cancer cells, as described hitherto, the geldanamycin derivatives of Chemical Formula 1 in accordance with the present invention can be applied to anticancer activity. Thus, a pharmaceutical composition comprising the derivatives according to the present invention as an active ingredient is useful in the prevention and treatment of various cancer diseases.
In addition, the geldanamycin derivatives of the present invention can be used as antibiotics, antifungal agents, anti- viral agents, immuno-suppressors, therapeutics for degenerative nerve diseases, anti-inflammatory agents, etc., because they show inhibitory activity against Hsp90, like geldanamycin.

Claims

[CLAIMS]
[Claim l]
A geldanamycin derivative represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:
<Chemical Formula 1>
Figure imgf000058_0001
(wherein,
X is -ORi or -NHR2 wherein Ri is Ci-C5 alkyl, and R2 is Ci~C5 alkyl, Ci-C5 alkenyl, mono- or di-Ci~C5 alkylamino-Ci~C5 alkylamino, halogen-substituted Ci-C5 alkylamino, or 3~7-atom- membered heterocycloalkyl-substituted Ci-Cs alkylamino, wherein the heterocycloalkyl contains at least one heteroatom;
Y and Z are independently hydrogen, -COR3 or -CONHR4 wherein R3 is Ci-C5 alkyl carbonyl-Ci~C5 alkyl and R4 is hydrogen or Ci-C5 alkyl; and carbon atoms at positions 4 and 5 may have a single bond or a double bond therebetween. )
[Claim 2]
The geldanamycin derivative according to claim 1 or the pharmaceutically acceptable salt thereof, wherein, X is -ORi or -NHR2. wherein Ri is Ci-C3 alkyl, and R2 is Ci~C3 alkyl, Ci-C3 alkenyl, mono- or di-Ci~C3 alkylamino-Ci~C3 alkylamino, halogen-substituted Ci-C3 alkylamino, or 3~5-atom- membered heterocycloalkyl-substituted Cx-C3 alkylamino, wherein the heterocycloalkyl contains least one heteroatom;
Y and Z are independently hydrogen, -COR3 or -CONHR4, wherein R3 is Ci-C3 alkyl carbonyl-Ci~C3 alkyl and R4 is hydrogen or Ci-C3 alkyl; and carbon atoms at positions 4 and 5 may have a single bond or a double bond therebetween.
[Claim 3]
The geldanamycin derivative according to claim 2 or the pharmaceutically acceptable salt thereof, wherein,
X is methoxy, ethylamino, allylamino, 2-N,N-dimethylamino- ethylamino, 2-N,N-diethylamino-ethylamino, 2-pyrrolidin-l- ylethylamino, 2-morpholin-4-ylethylamino, 3-imidazol-3- ylpropylamino or 2-fluoroethylamino;
Y and Z are independently hydrogen, acetylmethylcarbonyl, carbamoyl or methylcarbamoyl; and carbon atoms at positions 4 and 5 may have a single bond or a double bond therebetween.
[Claim 4]
The geldanamycin derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein the derivative is selected from a group consisting of:
1) carbamic acid 9-carbamoyloxy-8, 14, 19-trimethoxy- 4, 10, 12, lβ-tetramethyl-3, 20, 22-trioxo-2-aza- bicyclo[16.3.1]docosa-l (21) , 4, 10, 18-tetraen-13-yl ester; 2) carbamic acid 9-carbamoyloxy-19-ethylamino-8, 14- dimethoxy-4, 10,12, 16-tetramethyl-3, 20, 22-trioxo-2-aza- bicyclo[16.3.1]docosa-l (21) , 4, 10, 18-tetraen-13-yl ester;
3) carbamic acid 19-allylamino-9-carbamoyloxy-8, 14- dimethoxy-4, 10,12, 16-tetramethyl-3, 20, 22-trioxo-2-aza- bicyclo[16.3.1]docosa-l(21),4,10,18-tetraen-13-yl ester;
4) carbamic acid 9-carbamoyloxy-19- (2-dimethylamino- ethylamino) -8, 14-dimethoxy-4, 10, 12, lβ-tetramethyl-3, 20, 22-trioxo- 2-aza-bicyclo[lβ.3.1]docosa-l(21),4,10,18-tetraen-13-yl ester;
5) carbamic acid 9-carbamoyloxy-19- (2-diethylamino- ethylamino)-8, 14-dimethoxy-4, 10, 12, 16-tetramethyl-3,20,22-trioxo-
2-aza-bicyclo[16.3.1]docosa-l(21) , 4, 10, 18-tetraen-13-yl ester;
6) 3-oxo-butyric acid 8, 14, 19-trimethoxy-4, 10, 12, lβ- tetramethyl-3, 20, 22-trioxo-13- (3-oxo-butyryloxy) -2-aza- bicyclo[lβ.3.1]docosa-l(21) , 4, 10, 18-tetraen-9-yl ester; 7) methyl-carbamic acid 8, 14-dimethoxy-4, 10, 12, 16- tetramethyl-19-methylamino-13-methylcarbamoyloxy-3,20,22-trioxo- 2-aza-bicyclo[lβ.3.1]docosa-l(21) , 4, 10, 18-tetraen-9-yl ester;
8) carbamic acid 19-allylamino-9-carbamoyloxy-8, 14- dimethoxy-4, 10, 12, lβ-tetramethyl-3, 20, 22-trioxo-2-aza- bicyclo[lβ.3.1]docosa-l (21) ,4, β, 10, 18-pentaen-13-yl ester;
9) carbamic acid 9-carbamoyloxy-19- (2-dimethylamino- ethylamino) -8, 14-dimethoxy-4, 10, 12, 16-tetramethyl-3, 20, 22-trioxo- 2-aza-bicyclo[lβ.3.1]docosa-l (21) ,4, 6, 10, 18-pentaen-13-yl ester;
10) carbamic acid 9-carbamoyloxy-19- (2-diethylamino- ethylamino) -8, 14-dimethoxy-4, 10, 12, lβ-tetramethyl-3, 20, 22-trioxo- 2-aza-bicyclo[16.3.1]docosa-l(21) ,4, 6, 10, 18-pentaen-13-yl ester;
11) carbamic acid 9-carbamoyloxy-8, 14-dimethoxy- 4, 10, 12, 16-tetramethyl-3, 20, 22-trioxo-19- (2-pyrrolidin-l-yl- ethylamino)-2-aza-bicyclo[16.3.1]docosa-l (21), 4, 6, 10, 18-pentaen- 13-yl ester; 12) carbamic acid 19-ethylamino-13-hydroxy-8, 14-dimethoxy- 4, 10, 12, lβ-tetramethyl-3, 20, 22-trioxo-2-aza- bicyclo[lβ.3.1]docosa-l(21) , 4, 10, 18-tetraen-9-yl ester;
13) carbamic acid 19-allylamino-13-hydroxy-8, 14-dimethoxy- 4, 10, 12, lβ-tetramethyl-3, 20, 22-trioxo-2-aza- bicycle- [16.3. l]docosa-l (21) ,4, 10, 18-tetraen-9-yl ester;
14) carbamic acid 19- (2-dimethylamino-ethylamino)-13- hydroxy-8,14-dimethoxy-4, 10, 12, lβ-tetramethyl-3, 20, 22-trioxo-2- aza-bicyclo[16.3.1]docosa-l (21) , 4, 10, 18-tetraen-9-yl ester;
15) carbamic acid 19- (2-diethylamino-ethylamino) -13- hydroxy-8, 14-dimethoxy-4, 10,12, 16-tetramethyl-3, 20, 22-trioxo-2- aza-bicyclo[lβ.3.1]docosa-l (21) , 4, 10, 18-tetraen-9-yl ester;
16) carbamic acid 13-hydroxy-8, 14-dimethoxy-4, 10, 12, lβ- tetramethyl-3, 20, 22-trioxo-19- (2-pyrrolidin-l-yl-ethylamino) -2- aza-bicyclo [16.3.1] docosa-1 (21) , 4, 10, 18-tetraen-9-yl ester; 17) carbamic acid 13-hydroxy-8, 14-dimethoxy-4, 10, 12, 16- tetramethyl-19- (2-morpholin-4-yl-ethylamino) -3, 20, 22-trioxo-2- aza-bicyclo[16.3.1]docosa-l (21) ,4, 10, 18-tetraen-9-yl ester; and
18) carbamic acid 13-hydroxy-19- (3-imidazol-l-yl- propylamino) -8, 14-dimethoxy-4, 10, 12, lβ-tetramethyl-3,20,22- trioxo-2-aza-bicyclo[lβ.3.1]docosa-l (21) , 4, 10, 18-tetraen-9-yl ester.
[Claim 5]
A method for preparing a geldanamycin derivative, as elucidated in the following Reaction Scheme 2, comprising: reacting a starting material of Chemical Formula 2a with trichloroacetyl isocyanate in an organic solvent; and hydrolyzing the reaction product in the presence of excess AI2O3 to produce a compound of Chemical Formula Ia:
<Reaction Scheme 2>
Figure imgf000062_0001
3» 1a
[Claim 6]
The method according to claim 5, wherein the compound of Chemical Formula Ia, as elucidated in the following Reaction Scheme 3, is reacted with an amine compound in an organic solvent to produce a compound of Chemical Formula Ib: <Reaction Scheme 3>
Figure imgf000063_0001
(wherein, X is as defined in Chemical Formula 1]
[Claim 7]
A method for preparing a geldanamycin derivative, as elucidated in Route 1 of the following Reaction Scheme 4, comprising: reacting a compound of Chemical Formula 2a with diketene in presence of 4-dimethylaminopyridine (DMAP) and a base in an organic solvent.
<Reaction Scheme 4>
Figure imgf000064_0001
M
(wherein X is as defined in Chemical Formula 1 )
[Claim 8]
A method for preparing a geldanamycin derivative, as elucidated in Route 2 of the Reaction Scheme 4 of claim 7, comprising: reacting a compound of Chemical Formula 2a with 1,1'- carbonylimidazole in an organic solvent and then with an amine compound in the organic solvent.
[Claim 9]
A method for preparing a geldanamycin derivative, as elucidated in the following Reaction Scheme 5, comprising: reacting a compound of Chemical Formula 2b with trichloroacetyl isocyanate in an organic solvent; and hydrolyzing the reaction product in the presence of Al2O3 to produce a compound of Chemical Formula Ie:
<Reaction Scheme 5>
Figure imgf000065_0001
[Claim 10]
The method according to claim 9, wherein the compound of Chemical Formula Ie, as elucidated in the following Reaction Scheme 6, is reacted with an amine compound in an organic solvent :
<Reaction Scheme 6>
Figure imgf000065_0002
(wherein, X is as defined in Chemical Formula 1)
[Claim ll]
A method for preparing a geldanamycin derivative, as elucidated in the following Reaction Scheme 7, comprising: reacting a compound of Chemical Formula 2c with an amine compound in an organic solvent:
<Reaction Scheme 7>
Figure imgf000066_0001
(wherein, X is as defined in Chemical Formula 1)
[Claim 12]
The method according to one of claims 5 to 11, wherein the organic solvent is selected from a group consisting of dichloromethane, dichloroethane and tetrahydrofuran.
[Claim 13]
The method according to one of claims 6, 8, 10 and 11, wherein the amine compound is selected from a group consisting of ethylamine, allylamine, 2-N,N-dimethylamino-ethylamine, 2-N,N- diethylamino-ethylamine, fluoroethylamine, l-(2- aminoethyl) pyrrolidine, 4-(2-aminoethyl)morpholine and l-(3- aminopropyl) imidazole.
[Claim 14] An Hsp90 inhibitor, comprising a geldanamycin derivative represented by Chemical Formula 1 of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[Claim 15] An agent for the prevention and treatment of a cancerous disease, comprising a geldanamycin derivative represented by Chemical Formula 1 of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[Claim 16] The agent according to claim 15, wherein the cancerous disease is selected from a group consisting of breast cancer, liver cancer, stomach cancer, colon cancer, bone cancer, pancreatic cancer, head and neck cancer, uterine cancer, ovarian cancer, rectal cancer, esophageal cancer, small intestine cancer, periproctic cancer, cancerous Fallopian tube tumors, cancerous endometrioma, cancerous cervical tumors, cancerous vaginal tumors, cancerous vulval tumors, Hodgkin's disease, prostate cancer, bladder cancer, kidney cancer, ureter cancer, cancerous renal tumors, cancerous tumors of the renal pelvis and tumors in a central nervous system (CNS) .
[Claim 17]
An agent for use as an antibiotics, an antifungal, an antiviral, an immunosuppressor, a therapeutic for degenerative nerve diseases, or an anti-inflammatory, comprising the geldanamycin derivative of Chemical Formula 1 of claim 1 or a pharmaceutically acceptable salt thereof.
PCT/KR2007/004645 2006-09-29 2007-09-21 Geldanamycin derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and agent for the prevention and treatment of tumor containing the same as an active ingredient WO2008038964A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060095804A KR100796637B1 (en) 2006-09-29 2006-09-29 Geldanamycin derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and agent for the prevention and treatment of tumor containing the same as an active ingredient
KR10-2006-0095804 2006-09-29

Publications (1)

Publication Number Publication Date
WO2008038964A1 true WO2008038964A1 (en) 2008-04-03

Family

ID=39218779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/004645 WO2008038964A1 (en) 2006-09-29 2007-09-21 Geldanamycin derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and agent for the prevention and treatment of tumor containing the same as an active ingredient

Country Status (2)

Country Link
KR (1) KR100796637B1 (en)
WO (1) WO2008038964A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2415482A2 (en) * 2009-04-02 2012-02-08 Universidad del Pais Vasco Pharmaceutical compositions for treating metastasis
CN102731401A (en) * 2011-04-08 2012-10-17 杭州中美华东制药有限公司 Geldanamycin derivatives, preparation method thereof, and uses thereof
CN103804296A (en) * 2014-03-03 2014-05-21 山东大学 17-(6-(substituted cinnamon acylamino) hexanediamine-17-demethoxygeldanamycin derivatives and application thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101456173B1 (en) 2010-11-05 2014-10-31 한국생명공학연구원 Novel geldanamycin derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and agent for the prevention and treatment of tumor containing the same as an active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
KR20060014532A (en) * 2004-08-11 2006-02-16 한국생명공학연구원 Geldanamycin derivatives and the method for biosynthesis thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2268068T3 (en) * 2001-03-30 2007-03-16 The Usa, Represented By The Secretary, Dept. Of Health And Human Services National Institutes Health DERIVED FROM GELDANAMYCIN USEFUL FOR THE TREATMENT OF CANCER.
WO2003026571A2 (en) * 2001-09-24 2003-04-03 Conforma Therapeutics Corporation Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins
KR20020072815A (en) * 2002-08-27 2002-09-18 주식회사 태평양 Remedial agent for sepsis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
KR20060014532A (en) * 2004-08-11 2006-02-16 한국생명공학연구원 Geldanamycin derivatives and the method for biosynthesis thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2415482A2 (en) * 2009-04-02 2012-02-08 Universidad del Pais Vasco Pharmaceutical compositions for treating metastasis
EP2415482A4 (en) * 2009-04-02 2012-11-14 Univ Pais Vasco Pharmaceutical compositions for treating metastasis
CN102731401A (en) * 2011-04-08 2012-10-17 杭州中美华东制药有限公司 Geldanamycin derivatives, preparation method thereof, and uses thereof
CN103804296A (en) * 2014-03-03 2014-05-21 山东大学 17-(6-(substituted cinnamon acylamino) hexanediamine-17-demethoxygeldanamycin derivatives and application thereof

Also Published As

Publication number Publication date
KR100796637B1 (en) 2008-01-22

Similar Documents

Publication Publication Date Title
CN109790161B (en) Pyrazolopyridine derivatives having GLP-1 receptor agonist action
US7795457B2 (en) Carbamate compounds
McDonald et al. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer
US9745335B2 (en) N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application
US7446196B2 (en) Leptomycin compounds
EP3653625B1 (en) Fused ring derivative having mgat-2 inhibitory activity
Thanna et al. Synthesis and evaluation of new 2-aminothiophenes against Mycobacterium tuberculosis
CN105121443A (en) Certain protein kinase inhibitors
CN108137574B (en) Hydroxyalkyl thiadiazole derivatives
US20110136752A1 (en) Novel antibiotics
WO2008038964A1 (en) Geldanamycin derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and agent for the prevention and treatment of tumor containing the same as an active ingredient
CN113698401A (en) Beta-elemene macrocyclic derivatives, preparation method and application thereof
JP2010516282A (en) Macrolactam by engineering biosynthesis
EP3470410B1 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
CN112341390B (en) Compound for preparing targeted histone methyltransferase EZH2 covalent inhibitor and preparation method and application thereof
JP4047383B2 (en) Sesquiterpene derivatives with antiviral activity
WO2022122044A1 (en) Heterocyclic compound serving as gls1 inhibitor
JP5619001B2 (en) Streptspirol derivative
KR20080039470A (en) Novel ansamycin derivatives
JPWO2005061461A1 (en) Heat shock protein 90 (hsp90) family protein inhibitors
US8097709B2 (en) Macrolactam compounds
US20160311835A1 (en) Novel antibiotics
CN112920167A (en) Double-target inhibitor targeting FGFR and HDAC, preparation method and application thereof, pharmaceutical composition and medicament
CN115417877B (en) Histone deacetylase inhibitor and preparation and application thereof in preparation of anti-cancer drugs
WO2023233994A1 (en) Pharmaceutical composition and autophagy activator

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07808422

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07808422

Country of ref document: EP

Kind code of ref document: A1